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Glycosaminoglycans are becoming more and more focused upon as a research topic due to 
the broad use they have in aiding wound healing and preventing cell motility through 
competitive inhibition of the HGF-Met pathway. This pathway is extremely important in 
various cellular processes including cancer development, metastasis, tissue regeneration, 
damage and cell motility.   
This project aimed to synthesise a series of easily prepared (3 step) mono, di-, tri- and tetra-
sulfated glycomimetic compounds for their use in preventing HGF-induced cell motility in 
cancers, prevention of Met activation and for their beneficial actions in assisting wound 
healing.  
These compounds were prepared through 4 major synthetic routes:  
1) Coupling reaction of phenols with solketal, followed by deprotection of the acetonide and 
reaction of hydroxyl groups with SO3 complexes.  
2) Coupling phenols with allyl bromide, followed by asymmetric dihydroxylation and 
reaction of hydroxyl groups with SO3 complexes.  
3) Direct sulfation / sulfonation of phenols with SO3 complexes. 
4) Directed ortho-lithiation followed by exchange with an electrophile.  
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These compounds were tested for cell motility prevention by a wound healing assay and 
cytotoxicity was determined through a cell viability assay. 
Results showed that many of the compounds were easily synthesised in few steps and 
relatively high yields, with a number of the compounds demonstrating promising activity in 
slowing HGF-mediated cell motility at low µM concentrations, with motility being stimulated 
at higher concentrations. Further optimisation of the compounds with the highest activity 
along with further biological testing would help to ascertain a more certain SAR. 
Details of the compound observed with the highest efficacy (Compound 26) are shown in 
Figures 1-3. 
 
Figure 1. Graph showing percentage of wound still open after 24 hours following 
treatment with control drugs and varying concentrations of compound 26. 
Table 1. Percentage of wound still open after 24 hours 
NT HGF CRIZ 1 2 3 




























Scratch Assay after 24 hours: DAOY Compound 26
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Overall, several of the sulfated glycomimetic compounds synthesised in this project show 
promising activity in inhibiting the HGF/Met pathway, although more work is required to 
further optimise the SAR and assure effective inhibition.
 




1.1 . Hepatocyte Growth Factor: 
Hepatocyte Growth Factor (HGF) is an extremely important pleiotropic heparin-binding 
glycoprotein which is involved in cellular processes in virtually all multicellular organisms 
(Ricci, Catizone, & Galdieri, 2002; Yano, Tsuda, Ueda, & Higashio, 1998). HGF is commonly 
associated with the formation, repair and growth of cells and was initially purified through 
isolation from rat serum in 1984 (Buchstein et al., 2009; Mizuno & Nakamura, 2013). HGF 
has been documented as having significant roles in helping heal and repair damage, 
mediating various disorders with Oliveira et al., (2018) highlighting that HGF is a factor in 
one such disease: diabetes, more specifically in insulin resistance. They continue to explain 
that in individuals where insulin resistance is displayed, HGF is usually upregulated, along 
with other growth factor-like hepatokines which affect the way glucose reacts to several 
insulin sensitive cell types. Additionally, the receptor for HGF, c-Met is structurally similar to 
the insulin receptor, ISNR. This suggests that as the level of HGF increases, it can potentially 
interfere competitively with insulin, binding to ISNR and assisting insulin resistance (Fafalios 
et al., 2011). 
Other functions of HGF include tissue repair and cellular regeneration. Firstly, in relation to 
the repair of nerve cells, Ko, Lee, Lee, Nho, & Kim, (2018) explain that peripheral nerve 
regeneration in sciatic nerve injury was promoted through the increase of HGF released in 
areas of injury. Furthermore, when treated with a c-Met inhibitor, axon and myelin 
regrowth was decreased, demonstrating involvement of HGF and c-Met in nerve repair.  
 
 
2 | P a g e  
Alexander Bunte 
HGF is widely known to be heavily involved in the process of wound healing, allowing cells 
to proliferate and migrate enabling wounds to close, in addition to reducing inflammation 
and scarring (Dally et al., 2017). Dally et al., (2017) and Nakamura & Mizuno, (2010) go on to 
demonstrate that HGF is found to play a significant part in embryogenesis, tissue 
homeostasis, repair, regeneration, organ development and protection. It was found that 
during various organ diseases, the level of HGF is highly upregulated, likely as an attempt to 
repair any damage that may have been caused to any tissues (Nakamura & Mizuno, 2010). 
They further state that when the level of HGF was reduced through anti-HGF antibodies, the 
rate of degradation in tissue was observed to increase, demonstrating the role HGF plays in 
the maintenance of tissue function. 
HGF is secreted in its inactive form referred to as pro-HGF and activated in the body through 
a urokinase-type plasminogen activator (uPA) to αß-HGF through hydrolysis of an arginine-
valine bond, thus becoming the ligand for the tyrosine kinase Met (Naldini et al., 1995). 
Buchstein et al., (2009) goes on to explain that pro-HGF has a relatively uncommon 
structure in comparison to other growth factors which are generally much smaller and 
usually only single-domain proteins, whereas HGF is relatively large (92 kDa) and is a multi-
domain protein. This is further enforced by Naldini et al., (1995) and Dally et al., (2017), who 
explain that αß-HGF is comprised of a 55-60 kDa α domain which contains a N-terminal 
hairpin loop and 4 kringles (NK1-NK4), which allow binding and activation of the receptor. 
There is also the 32-34 kDa ß domain which contains a secondary receptor binding site 
linked through a disulfide bridge as a heterodimeric protein. This then exists as 3 major 
isoform variants: HGF-NK, NK1 and NK2, where NK1 is an agonist to c-Met and NK2 is a 
partial c-Met antagonist. 
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Figure 4. Domain structures of α and ß HGF chains (a) Crystal structure of NK1 and SPH 
domains (b). Reprinted from “Met, metastasis, motility and more” by Birchmeier, C., 
Birchmeier, W., Gherardi, E., & Vande Woude, G. F. 2003. Nature Reviews Molecular Cell 
Biology, 4(12), 915–925.  
Nakamura & Mizuno, (2010) explain that HGF is produced by stromal cells and is involved in 
stimulating many cellular functions such as angiogenesis, cell motility, cell proliferation, and 
morphogenesis. This is then a particular target for anticancer drugs as it shows activity in 
many human cancer pathways. This further assists the progression of tumour cells whilst 
aiding metastasis through increasing cell motility (Matsumoto & Nakamura, 1997). Targeting 
HGF, and consequently its receptor the tyrosine kinase Met, allows reduction in the activity 
of the HGF-Met pathway. Focussing on treating this pathway in cancer may achieve reduced 
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mortality rates, as the rates of tumour progression, angiogenesis, and metastasis would be 
minimised thus leading to potentially less aggressive and slower growing cancers (Cecchi, 




Met is a Receptor Tyrosine Kinase (RTK) which are a class of cell surface receptors primarily 
involved in signalling pathways of most cancers. This is largely due to their ability to control 
cellular invasion, proliferation, cancer cell regulation and angiogenesis which have a distinct 
role in the manifestation of many cancers (Maroun & Rowlands, 2014). All 518 known 
human RTKs have similar molecular structures, which further fall into 20 subfamilies, all 
sharing three common features: a ligand binding region in the ECM, a singular 
transmembrane helix and a cytoplasmic region that contains the tyrosine kinase, in addition 
to the carboxy terminal and juxtamembrane regions (Lemmon & Schlessinger, 2010). 
The Met pathway is initiated through the binding of HGF to Met, resulting in dimerisation 
followed by autophosphorylation of two tyrosine residues.  This in turn activates further 
downstream signalling pathways, in particular MAPK and PI3K, resulting in cell 




5 | P a g e  
Alexander Bunte 
 
Figure 5. Dimerisation of inactive monomers to form the active RTK dimer. Adapted from 
“Cell Signaling by Receptor Tyrosine Kinases” by Schlessinger, J. 2000. Cell, 103(2), 
211-225. 
Met is a key example of this; in many cancers it is overexpressed. This is especially seen in 
non-small cell lung, gastrointestinal and hepatocellular carcinomas due to Met being the 
major pathway affecting cancer progression rate as suggested by Maroun & Rowlands, 
(2014). They suggest that its ability to communicate with the vascular endothelial growth 
factor receptor (VEGFR), results in upregulated angiogenesis and endothelial cell growth. 
This is reinforced by Cecchi et al., (2012) and Maroun & Rowlands, (2014) who explain that 
elevated Met and HGF levels as a result of mutations to Met generally lead to a poor 
prognosis for the sufferer due to the increased activity allowing primary cancer effecting 
pathways to function unchecked. Organ & Tsao, (2011) further support this by explaining 
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that some cancers can be “addicted” to Met expression (oncogene addiction) and require it 
to support tumour growth and survival of the cancer itself.  
In terms of selecting Met as a target for anticancer drugs and therapies, there are 3 main 
routes: a) preventing the combination of HGF and Met extracellularly, b) preventing 
phosphorylation of the tyrosine domain, and c) inhibiting Met kinase-dependent signalling 
(Maroun & Rowlands, 2014). When targeting Met, HGF is found to be the sole co-factor 
ligand. This allows us to select Met as an effective target for anticancer drugs due to both 
Met’s activation of a large range of its own and other receptors’ oncogenic processes in 
addition to the fact that there is only one known ligand in which anticancer drugs would be 
competing, in order to inhibit the pathway effectively (Dua, Zhang, Parry, & Penuel, 2011).  
Met possesses a very complex structure due to it being a transmembrane bound receptor 
with several extracellular (Sema, PSI, IPT) and intracellular domains (Juxtamembrane, 
Kinase) and a multifunctional docking site (Organ & Tsao, 2011). Met is initially secreted as 
an inactive single-chain molecule that is then cleaved between residues 307-308, resulting 
in the production of a disulfide-bridged heterodimer (Birchmeier, Birchmeier, Gherardi, & 
Vande Woude, 2003). Cleavage of an inactive form of Met to give the active form is similar 
to the way active HGF is produced, as discussed earlier, pro-HGF is cleaved to form active 
HGF.  Structurally, Met is comprised of a cysteine domain attached to four immunoglobulin 
domains which are suggested to hold the ß chain of the protein in such a way that it allows 
binding of its ligand, HGF resulting in the activation of the HGF-Met pathway (Birchmeier et 
al., 2003).  
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Figure 6. Transmembrane domain structure of Met. Reprinted from “An overview of the c-
MET signaling pathway” by Organ, S. L., & Tsao, M. S. 2011. Therapeutic Advances in 
Medical Oncology, 3(1), S7–S19. 
Other RTKs are able to be targeted through the use of drugs such as cabozantinib, an 
inhibitor for Met, VEGFR2, AXL, KIT, KIE2, FLT3 and RET kinases. This targets multiple RTK 
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pathways at the same time, allowing increased survival rates due to the level of kinase 
inhibition when compared to other drugs like erlotinib (Maroun & Rowlands, 2014). They 
report that in a phase II randomised and controlled clinical trial investigating the efficacy of 
cabozantinib and erlotinib alone, versus a combination of the two, was found that in 
patients with advanced NSCLC, erlotinib alone gave 1.8 months of progression free survival 
(PFS) whereas cabozantinib gave 4.3 months. This demonstrates the effectiveness of a 
multi-kinase inhibitor (cabozantinib) versus a single EGFR inhibitor (erlotinib). However, a 
combination of the two gave 4.7 months of PFS, an increase over drug monotherapy 
showing that inhibiting many RTK pathways will generally increase the level of PFS.  
 
 
1.3. Cell Motility: 
Cell motility is a process which is involved in various critical bodily processes and diseases, 
namely wound repair, tissue growth and cell invasion in metastatic cancers. In cancer it is 
rarely the primary tumour that is the cause of death, rather the formation of various 
metastases throughout the body as a result of malignant cells moving and uncontrollably 
growing in remote tissues (Yilmaz & Christofori, 2010). They continue to explain that cells 
can migrate both as a group, or as single cells with several processes being undertaken 
during the migration. During this the cell itself changes at the molecular level through 
modification to its cell-cell and cell-matrix adhesion and the actin cytoskeleton. However, as 
of yet the understanding of how cells physically migrate out of tissues, survive immune 
detection and response, and begin metastasis in distant tissues is not fully known.  
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Jiang et al., (2015) describe that cell adhesion and inter-cellular structures are the primary 
factors in maintaining a single tumorous mass, and failures of these structures may lead to 
cells spreading out from the tumour and forming metastases.  Jiang et al., (2015) and 
Stuelten, Parent, & Montell, (2018) both introduce the role of the E-cadherin “switch” which 
in most epithelial cell mediated cancers show loss of functionality. They clarify that loss of 
the “switch” in cancers leads to reduced cellular adhesion, increasing the chance of cancer 
cells detaching from the primary tumour and migrating. In addition to this, loss of contact 
inhibition allows these cells to have unchecked cellular growth and therefore support the 
process of secondary tumour growth (Cavallaro & Christofori, 2004). 
Another process which leads to similar effects to that of the E-cadherin “switch” is EMT 
(epithelial-mesenchymal transition). This is a differentiation which epithelial cells undergo in 
order to morph into a mesenchymal phenotype. This is achieved through a series of 
biochemical modifications to the cell (Kalluri & Weinberg, 2009). Completion of this 
modification enables the cells to have an increased level of motility, invasiveness and the 
ability to resist apoptotic signals that are characterised by the deterioration of the basement 
membrane. Subsequent formation of mesenchymal cells enables them to migrate away 
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Figure 7. Role of EMT in cancer metastasis. Reprinted from “The basics of epithelial-
mesenchymal transition” by Kalluri, R., & Weinberg, R. A. 2009. Journal of Clinical 
Investigation, 119(6), 1420–1428.  
Normal and malignant cells are said to generally migrate through amoeboid, mesenchymal 
or individual pathways (Stuelten et al., 2018), or collective cell migration in cellular sheets, 
strands, clusters and tubes (Jiang, Li, He, & Zhao, 2013). The format of cell migration is 
dependent on the cell type; epithelial cells usually migrate in sheets, whereas colorectal 
cancer cells disseminate as single, solitary cells (Yilmaz & Christofori, 2010). 
As tumour metastasis is the primary death factor in 90% of cancer related deaths, selecting 
this as a target for anticancer drugs would be a credible choice, as the inhibition of signalling 
pathways such as EGFR, HGF-Met, FGFR and IGF1R which are involved with cell movement, 
proliferation, differentiation and survival could reduce the level of both primary tumour size 
and metastasis formation, making treatment a much more streamlined, specific, less toxic 
and more successful approach (Leber & Efferth, 2009; Yilmaz & Christofori, 2010). 
Cell motility is also essential to wound healing, utilising various processes such as EMT and 
scatter factor mediated collective cell migration to close up wounds through the directional 
migration of a cell sheet, in addition to increased epithelial cell proliferation and the 
following migration of cells to the centre of the wound, allowing wound closure and 
therefore repair (Jiang et al., 2013). 
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1.4. Glycosaminoglycans: 
Glycosaminoglycans or GAGs are one of the most complex of the four major sulfated 
polysaccharide biopolymers found generally on cell surfaces and in the extracellular matrix 
(ECM) within mammals, and have been found to be a very worthwhile target for the 
development of new drugs, nanoparticles and imaging agents for use in cancers and healing 
medicines through the mimicry of GAGs and proteoglycans (PGs) (Yamada, Sugahara, & 
Özbek, 2011). 
These are found primarily as glycolipids or PGs in the body, bound to cell membrane protein 
and lipids respectively, and are usually comprised of alternating units of N-acetyl-D-
glucosamine (GlcNAc), or N-acetylgalactosamine (GalNAc) and a hexuronic acid (HexA), 
being either glucuronic acid (GlcA) or iduronic acid (IdoA) (Scott & Panitch, 2013; Yamada et 
al., 2011). It has been also discovered that some PGs are substituted with multiple GAG 
chains, for example syndecan-1 (heparan sulfate, chondroitin sulfate) and aggrecan (keratan 
sulfate, chondroitin sulfate). This increases the level of structural diversity of the GAG 
family, as PGs are usually classed by their location, basement membrane, ECM and GAG 
substitution pattern (Yip, Smollich, & Götte, 2006). Scott & Panitch, (2013) continue to 
explain that the monomer units of GAGs and PGs have sulfation patterns that vary across 
the monomer units, with GlcA being sulfated on carbon 2 and/or 3, whereas GalNAc is 
usually sulfated on carbons 4 and/or 6. 
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Figure 8. Structures of Chondroitin Sulfate (CS), Dermatan Sulfate (DS), Heparan Sulfate 
(HS) and Hyaluronic Acid (HA). Reprinted from “Evolution of glycosaminoglycans: 
Comparative biochemical study” by Yamada, S., Sugahara, K., & Özbek, S. 2011. 
Communicative and Integrative Biology, 4(2), 150–158. 
Sulfation in these molecules is a key feature, as the presence of multiple -SO3 groups each 
providing a negative charge allows for a high level of anionic charge density, therefore giving 
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GAGs the ability to increase osmotic pressure around areas which are highly saturated with 
GAGs (Scott & Panitch, 2013). Scott & Panitch, (2013) further explain that the anionic quality 
of these molecules facilitates their ability to interact as several growth factors, cytokines 
and proteases. 
Yamada et al., (2011) and (Yip et al., 2006) explain that GAGs are involved in a range of 
important roles throughout the body, the focus being on cell growth and differentiation, 
morphogenesis, angiogenesis, cell adhesion, cell signalling, inflammation, cell migration and 
wound healing. This gives GAGs a strong foundation in many physiological processes which 
may facilitate the development of new drugs and treatments for a wide range of diseases in 
the form of anticancer, anticoagulant, antithrombotic and wound healing drugs (Volpi, 
2006). Cancer is a key example, as GAGs and PGs are known to be dysregulated in various 
cancer pathways, generally correlating to the severity of the prognosis (Yip et al., 2006). 
They continue to illustrate that cancer cell GAGs and PGs can influence several factors of the 
cancer itself in the way of reduced cell adhesion, increased cell invasion, motility and 
angiogenesis, this being a major factor in determining the cancer’s invasiveness and growth 
rate.  
One such example of this is Heparan Sulfate (HS) which in transformation from colon 
adenoma to carcinoma is seen to have a reduction in the level of sulfated sites when 
compared to normality. This strongly influences the function of the molecule, resulting in 
increased cancer progression and is also observed across ovarian, squamous cell and 
hepatocellular carcinomas (Yip et al., 2006).  Afratis et al., (2012) and Belting, (2014) suggest 
that an oversulfated HS mimic would have strong anti-tumour effects, as this inhibits various 
tumour cell functions through promotion of phenotype transformation.  This results in 
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suppression of processes involved in further progression of the cancer as well as inhibiting 
interactions with growth factors and cytokines such as the HGF-Met pathway through their 
HS chains. These are largely responsible for cell motility and proliferation. Furthermore, HS 
has uses outside of cancer treatment as suggested by Yamada et al., (2011) who explain that 
oversulfated HS could have a role in the protection of tissues in direct environmental 




This project aimed to synthesise a series of mono, di, tri and tetra-sulfated 
glycosaminoglycan mimics and investigate their functionality in both reducing the level of 
HGF-induced cell motility and their ability to inhibit the activation of the Met pathway 
through HGF. 
Synthesis of these glycomimetic compounds was the major focus of this project and was 
achieved in 1-4 steps depending upon the molecule being synthesised. Three major 
categories of compounds were synthesised during this project: 
a) Enantioenriched benzonitrile glycomimetics – through coupling with allyl bromide, 
followed by asymmetric dihydroxylation and sulfation (Compounds 12 + 13). 
b) racemic benzonitrile glycomimetics – through coupling with solketal, deprotection of the 
acetonide, and sulfation of the vicinal diol (Compounds 6, 8 + 17). 
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c) aryl sulfated and sulfonated glycomimetics – through direct sulfation and sulfonation of 
OH groups on substituted phenols (Compounds 24 – 30). 
Following synthesis of glycomimetic compounds, subsequent testing on DAOY 
medulloblastoma cells was performed to investigate firstly, their ability to reduce cell 
motility in wound healing assays and secondly, to ascertain whether the compound has any 
effect on cell viability, as we are aiming to prevent cell mobility while having little to no 
effect on cell viability. These tests would show us if the compounds synthesised here would 
have any effect on cell proliferation, motility or Met inhibition. Successful results in slowing 
wound healing and high cell viability counts would suggest effective inhibition of HGF-Met, 
with little cytotoxicity, and would therefore lend itself as a good candidate for use as an 
anti-cancer drug. Conversely, should the compound show increased cell proliferation and 




2. Results and discussion: 
2.1. Synthetic Overview: 
This project addresses 6 major synthetic pathways (A – F) in preparation of a series of novel 
glycomimetic compounds for testing on DAOY cells in order to determine efficacy.  
 
 




Figure 9. Synthetic pathway A - Preparation of 3-cyano substituted glycomimetics. 
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Compounds 2 - 13 were derived from 3-cyanophenol, and the reaction pathway split into 3 
distinct sub routes:  
 
Figure 10. Sub-route A-1 - Preparation of 5-substituted racemic sulfates. 
These compounds were formed by firstly reacting N-bromosuccinimide with 3-cyanophenol 
by electrophilic aromatic substitution to give compound 2 in high yield (92%). This was then 
coupled with solketal through the Mitsunobu reaction which exhibited some difficulty in 
purification and isolation of the compound to yield 43% of compound 3. This low yield is 
likely due to loss of product through the multiple purification steps undertaken required to 
remove contaminants. Additionally, some cleavage of the acetonide may have occurred 
during column chromatography due to the acidic nature of silica resulting in a portion of the 
product eluting as the diol at a different point, resulting in loss of yield. 
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Subsequently, the acetonide was cleaved using p-toluenesulfonic acid to give the vicinal 
diol, compound 4 in a moderate yield (50%). This low yield is attributed to having worked on 
a very small scale, as considerable amounts of product can be lost in various simple steps 
such as transfer of the compound between glassware, with some quantity of product 
becoming unrecoverable both from traces left on glassware used and in the aqueous waste 
left over following the workup. Furthermore, we have seen that small-scale workups are 
usually relatively inefficient, firstly due to the issues discussed earlier, and secondly to the 
fact that comparatively large amounts of solvent and water are required to allow for ease of 
handling, therefore facilitating successful isolation of product. 
Once successful deprotection of the acetonide was achieved, the diol was then sulfated to 
give the glycomimetic, compound 6 in high yield (91%). Sulfation of these 2,3-diols is facile 
and requires low temperatures over an extended reaction period. Purification poses some 
challenges, as aqueous extraction is not viable due to the solubility of the sulfate. Therefore, 
solvent must be removed under high vacuum, followed by column chromatography in 
methanol to yield the pure sulfate. Ways to mitigate this have been achieved and is 
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Figure 11. Sub-route A-2 - Preparation of 2,5-substituted stereorandom sulfates. 
 
Following synthesis of 5-substituted sulfates, compound 3 was utilised to produce a 2,5-
substituted sulfate 8 which was achieved through coupling a second molecule of solketal to 
compound 3 through an Ullmann-type reaction to give compound 5 (95%). This reaction 
functioned extremely well, and a further series of bis substituted sulfates with varying 
positions should be investigated using this method as chlorine-substituted arenes are 
relatively common and easy to obtain from chemical suppliers. 
Compound 5 was deprotected with use of Amberlyst 15 H+ resin as an acidic source to give 
the bis diol compound 7 (50%), resulting in a moderate yield. This again may have been due 
to loss through transfer and workup, although some of this loss may have been due to 
degradation of the molecule from the acidic conditions resulting in loss through in the 
 
 
20 | P a g e  
Alexander Bunte 
workup. There is also the potential for the product to bind to the ion exchange resin, 
ultimately being lost upon discarding the used resin, this should be investigated in order to 
mitigate losses. 
Sulfation of the bis diol was then completed to give the final glycomimetic compound 8 
(83%). As with compound 6, solvent needed to be removed through high vacuum followed 
by methanol column chromatography to give the pure sulfate. 
 
Figure 12. Sub-route A-3 - Preparation of 2,5-substituted enantio-enriched sulfates. 
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Preparation of compound 9 was accomplished through allylation of compound 1 and gave 
the product in good yield (95%). 
Subsequent Sharpless asymmetric dihydroxylation was undertaken to give the 
enantioenriched S (compound 11) and R (compound 10) 2,3-diols in 82% and 87% yields 
respectively. Asymmetric dihydroxylation of simple alkenes is very easy but has some 
drawbacks in the form of extended reaction times and low temperatures (>12 h, 0 °C) which 
can require specialist equipment. High yields and success rates are almost always observed 
from this reaction, making it an effective way to form enantiomeric diols (Hentges & 
Sharpless, 1980). Due to our inability to measure the e.e of these enantioenriched 
compounds, it was assumed to be successful due to preceding literature demonstrating 
success with similar substrates and conditions. 
Following this, compounds 10 and 11 were then sulfated to give the enantioenriched S and 
R sulfates (compounds 12 and 13) in good yields of 79% and 76%. In this case a different 
sulfation method was utilised, using sulfur trioxide tributylamine complex, which allows for 
an aqueous workup, making purification much easier (Gill, Male, & Jones, 2019). 
Furthermore, this method introduced an integral sodium salt exchange step, allowing simple 
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Figure 13. Synthesis of sulfur trioxide tributylammonium complex. 
 
Figure 14. Synthetic pathway B - Preparation of 5-chloro substituted sulfates. 
Synthesis of compound 15 was attained by nucleophilic aromatic substitution of compound 
14 with solketal and gave a good yield of 76%. A disubstituted variant of this molecule was 
attempted, compound 43 (Figure 15), however the electron donating effect from the 
acetonide and the loss of a chlorine electron withdrawing group, greatly deactivates the ring 
preventing further substitution. This reaction proceeds with relative ease and efficiency and 
it would be worthwhile investigating its use in other syntheses, where chlorine is in a 
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Following nucleophilic substitution, compound 15 was then deprotected using Amberlyst 15 
H+, utilising the same method used in previous deprotections to give compound 16 at a high 
yield of 0.166 g, 93%. As with previous deprotections, this proceeds without issue, giving the 
vicinal diol. 
 
Figure 15. Failed synthesis of compound 43. 
Compound 16 was sulfated using the basic sulfation method (sulfur trioxide trimethylamine 
complex, DMF, 40 °C, 16 h), to give the glycomimetic compound 17 in high yield (83%). This 
sulfate was subjected to the same isolation and purification methods as described earlier to 
give the pure sulfated compound. 
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Figure 16. Synthetic pathway C - Synthesis of compounds 24 – 30. 
Compounds 24-30 were prepared by reaction of the chosen substituted phenol with SO3 
pyridine complex at reflux in toluene to give the corresponding aryl glycomimetic. 
Potassium salts were obtained through treatment of the sulfate with 0.2M KOH. Synthesis 
of these simple glycomimetics was sustained at high yields throughout the series of 
compounds, likely due to the simplicity of the reaction and purification steps. 
Compound 30 is an exception to the general conditions, requiring a different set of reaction 
conditions (chlorosulfonic acid, dichloromethane, room temperature, 16 h), to yield the 
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trisulfate rather than the trisulfonic acid 26, which is produced when the general procedure 
is used. 
Table 2. Yields of compounds 24 - 30. 
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Figure 17. Synthetic pathway D - Preparation of 2,2-dimethyl-4-(phenoxy)methyl-1,3-
dioxolane. 
Compound 37 was investigated as we were attempting to determine a synthetic step which 
would allow us to couple substituted phenols with solketal, without the use of the 
Mitsunobu reaction, which had proved somewhat unsuccessful for us. However, this was 
found to be even more labour intensive as the formation of compound 37 was not achieved 
in good yield without the use of a tosylate intermediate which required prior preparation. 
Synthesis of compound 33 was attempted through asymmetric dihydroxylation of 
compound 31, and then protection of the diol (compound 32) to form the acetonide, 
compound 33. However, this was found to be inviable as only a small percentage of 
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acetonide was formed in the protection step even with considerably extended reaction 
times. 
We therefore synthesised the protected diol (compound 37) through a more involved route 
utilising solketal tosylate (compound 35) formed through coupling of solketal with tosyl 
chloride (compound 34). This tosylate intermediate allowed us to prepare compound 37 
easily in one step. This route was also not without its difficulties however, as the initial 
attempt at the synthesis was met with failure, yielding compound 35 in a low amount of 
product. This was due to contamination of the tosyl chloride with p-toluenesulfonic acid 
resulting in subsequent deprotection of the acetonide in situ. We resolved this through 
purification of the tosyl chloride by Soxhlet extraction with petroleum ether to exclude any 
p-toluenesulfonic acid.  
The reaction was repeated with the purified tosyl chloride, and yielded compound 35 in a 
high yield of 89% which was then used to synthesise compound 37 in a moderate yield of 
48%.  
 
Figure 18. Synthetic pathway E - Determination of lithiation conditions. 
Lithiation of this compound was investigated in order to determine whether ortho lithiation 
was attainable on substrates similar to compound 37. In order to determine the correct 
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conditions for ortho lithiation, it was decided to run several trial reactions utilising the same 
materials with varying conditions, as shown in table 3. in section 3.2.16. Reactions were 
quenched with D2O, to achieve lithium - deuterium exchange. This was followed by 1H NMR 
spectroscopy, allowing us to determine reaction success quantitatively. Loss of 1 aromatic 







Figure 19. Synthetic pathway F - Preparation of substituted diarylmethanes. 
Substituted diarylmethanes were selected for synthesis and subsequent investigation, due 
to the lack of data available for more complex multi-ringed sulfates. A diarylmethane 
species was selected, as the coupling of the phenyl rings were able to be both easily joined 
through a simple lithium cross coupling reaction in one step while directing the coupling to 
the desired ortho position on compound 39. 
The synthesis of these was attempted through reaction of compound 39 with 3-
(bromomethyl)benzonitrile by directed ortho lithiation to give the substituted 
diarylmethane, compound 40 at a yield of 63%. 
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Due to time constraints, this synthesis was never completed. However, given more time, 
this would be a worthwhile area to continue research, as diarylmethane-based 
glycomimetics have not been investigated thoroughly as of yet. 
 
 
2.2. Synthesis of enantio-enriched diols: 
 
Figure 20. Synthesis of (R)-3-(2,3-dihydroxypropoxy)benzonitrile. 
Synthesis of enantiomeric vicinal diols such as (R)- and (S)-3-(2,3-
dihydroxypropoxy)benzonitrile by Sharpless asymmetric dihydroxylation have been 
documented in literature to a large extent (Elsevier, 2019). Synthesis of these compounds 
was achieved through preparation according to the route taken by Raiber et al., (2007) in 
which, a substituted phenol was reacted with allyl bromide to give the O-allyl species, an 
example of which can be seen in Figure 20 as compound 9, 3-allyloxybenzonitrile. Coupling 
of allyl groups generally shows a very specific set of peaks in the product, 6.05 ppm (m, 1H), 
5.48 ppm (dd, 1H), 5.40 ppm (dd, 1H) and 4.55 ppm (d, 2H). Aromatic peaks integrate to 1 : 
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1 : 2 at 7.45 – 7.1 ppm, signifying 4 aromatic protons, as expected . These are easily 
observed in Figure 21, signifying a successful reaction.  
This was followed by Sharpless asymmetric dihydroxylation to give the vicinal diol 
enantiomer. Both the allylation and asymmetric dihydroxylation (AD) reactions always seem 
to proceed with yields above 80% and require little to no purification, even on large scales. 
These procedures were repeated to give both (R)- and (S)- 3-(2,3-
dihydroxypropoxy)benzonitrile which were then subjected to sulfation outlined in section 
2.5.  
 
Figure 21. 1H NMR of 3-allyloxybenzonitrile.  
Although AD reactions are very simple to carry out, due to commercial AD reagents being 
readily available for use from various suppliers, they do however require a relatively long 
reaction time (>12 h) in addition to maintaining constant cooling at 0 °C throughout the 
whole duration of the reaction. Maintaining the low temperature can prove to be somewhat 
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challenging without available specialist equipment to hand. Given that we do not have a 
way to monitor our e.e, we can assume that a good e.e would be achieved due to preceding 
literature reporting that low temperatures, and high pH in asymmetric dihydroxylation, yield 
a good e.e, and as temperature increases and pH decreases, e.e tends to suffer 
(Mehltretter, Dobler, Sundermeier, & Beller, 2000). 
A way to overcome this could be to utilise the Mitsunobu reaction, as discussed in section 
2.2, using pre-purchased optically pure (R)-(-) and (S)-(+)-solketal and then coupling it with 
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Figure 22. 1H NMR, 13C NMR and structure of (R)-3-(2,3-dihydroxypropoxy)benzonitrile. 
Figure 22 shows successful formation of the vicinal diol through asymmetric 
dihydroxylation, as peaks at 4.19 ppm (d, 1H), 4.05 ppm (m, 1H) and 3.2 ppm (d, 1H) in the 
1H NMR spectrum assign to the 5 protons present on the alkyl chain, in addition to aromatic 
protons integrating to a total of 4 (1 : 3) at 7.53 – 7.25 ppm. The shift upfield indicates the 
presence of oxygen, which combined with peak assignment, demonstrate successful 
synthesis. The 13C spectrum helps confirm this, as the peaks at 64.96, 65.02 and 75 ppm 
confirm the presence of the alkyl chain with a slight amount of impurities upfield. 
 
 
2.3. Synthesis of racemic diols through coupling with solketal:  
Solketal was chosen as the primary reagent in this synthesis for preparing a series of nitrile-
substituted arenes with 1-2 (2,3-dihydroxypropoxy) chains per molecule. Solketal seemed to 
be the most logical choice, as it enabled us to easily couple substituted benzonitriles with 
itself. This was followed by deprotection of the acetonide to give the vicinal diol with little 
difficulty. Solketal benefits from the 2,3 diol being by an acetonide. This allows further 
reactions to be carried out following the initial solketal coupling, as the acetonide may be 
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left untouched, subsequent reactions can then be carried out without modification of the 
initial chain, followed by deprotection of the acetonide in one step. 
One such example of this can be seen in our preparation of compound 3 from its starting 
material, 2-bromo-5-hydroxybenzonitrile (Figure 23).  In this case, the Mitsunobu reaction 
was used to couple the first solketal molecule with the hydroxyl group, yielding compound 
3. 
 
Figure 23. Synthesis of 2-bromo-5-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]benzonitrile. 
While leaving the diol protected, an additional solketal molecule was added to 2-bromo-5-
[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]benzonitrile though an Ullmann-type reaction, in 
which the aryl bromine was substituted by solketal. Both acetonides could then be cleaved 










Figure 24. Synthesis of 2,5-bis-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]benzonitrile and 
2,5-bis-(2,3-dihydroxypropoxy)benzonitrile from 2-bromo-5-[(2,2-dimethyl-1,3-dioxolan-4-
yl)methoxy]benzonitrile using sub-route A – 2. 
 
The reactions used in these couplings are as follows: 
1) Mitsunobu Reaction: 
In our aim to prepare a phenyl ether, the Mitsunobu reaction was selected due to its proven 
history of being predictable and successful, while using relatively cheap and readily available 
laboratory reagents. While we were initially successful in coupling solketal to 2-bromo-5-
hydroxybenzonitrile using standard conditions as seen in Figure 10, subsequent attempts to 
prepare further quantities met with failure. There may be several explanations for this, as 
the Mitsunobu reaction can prove to be difficult for a number of reasons. 
Firstly, one of the reagents necessary for successful ether formation within the Mitsunobu 
reaction is an azo-reagent such as diisopropyl azodicarboxylate (DIAD) or diethyl 
azodicarboxylate (DEAD). This is required to form the triphenylphosphine adduct 
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(Mitsunobu, 1981). Unfortunately, Azo-reagents such as DIAD and DEAD are extremely 
sensitive both to light, moisture and heat and when given enough exposure, breaks down 
leading to reaction failure (Yang, Dai, Wang, & Chen, 2011). There is concern about using 
these reagents in terms of their safety, as when subjected to heating above 100 °C, 
explosive decomposition occurs and can pose a significant safety hazard in the laboratory 
(Sigma Aldrich, 2019). 
This can be easily remedied by purchasing small quantities of the reagent and using them on 
a single use basis, although this can result in high per-reaction costs. Upon completion of 
the reaction, 2 major by-products are formed, reduced DIAD and TPPO (triphenylphosphine 
oxide), which can be seen in Figure 25 at 5 ppm and 1.3 ppm (DIAD), and 7.4 – 7.75 ppm 
(TPPO) in large quantities. Both of these by-products can prove difficult to remove using 
standard purification techniques, such as flash column chromatography, with reduced DIAD 
generally co-eluting with product (Yang et al., 2011). TPPO can also be problematic, as large 
quantities of it remain following reaction completion and can cause issues such as 
precipitation in the column, in addition to sharing the problem of co-elution as with reduced 
DIAD (Falconer, Jablonkai, & Toth, 1999). Ways to mitigate this have been developed, such 
as the method suggested by Batesky, Goldfogel, & Weix, (2017) where TPPO is reacted with 
zinc chloride, and precipitated out as a zinc complex, therefore avoiding the need for 
difficult and lengthy columns. 
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Figure 25. 1H NMR showing 2-bromo-5-[(2,2-dimethyl-1,3-dioxolan-4-
yl)methoxy]benzonitrile contaminated with TPPO and reduced DIAD. 
Secondly, this reaction proceeds more successfully when moisture is excluded, this 
significantly increases the difficulty in setting up and maintaining conditions throughout the 
reaction, due to the sensitivity of the azo-reagent with moisture, as described earlier. 
Reagent addition order is also important here, as the phosphonium – azo adduct must first 
be prepared at 0 °C, to prevent heating and decomposition of the azo-reagent. This is 
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followed by addition of the substrate, then nucleophile (Varasi, Walker, & Maddox, 1987). 




























Figure 26. 1H NMR, 13C NMR and structure of 2-bromo-5-[(2,2-dimethyl-1,3-dioxolan-4-
yl)methoxy]benzonitrile. 
Following purification, it is able to clearly see the peaks in both spectra for the presence of 
the solketal chain, shown below. 
1H NMR - 4.36 - 4.40 ppm (m, 1H), 4.10 ppm (dd, 1H) 3.86 – 4.00 ppm (m, 2H) 3.81 ppm (dd, 
1H), 1.38 ppm (s, 3H) and 1.33 ppm (s, 3H). 
13C NMR - 110.10, 73.66, 69.42, 66.41, 26.75 and 25.26 ppm. 
Additionally, aromatic protons can be seen integrating to 1 : 1 : 1 at 7.0 – 7.6 ppm, for a 
total of 3, which together demonstrate reaction success. 
Ways to mitigate purification problems in the Mitsunobu reaction have been developed in 
the form of new, more advanced reagents and variations in the reaction itself. 
Replacements for both DIAD and TPP in the forms of Di-p-chlorobenzyl azodicarboxylate 
(Lipshutz, Chung, Rich, & Corral, 2006) and polymer-supported TPP (Tunoori, Dutta, & 
Georg, 1998) have been discovered and function identically to the original reagents, 
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Furthermore, Beddoe et al., (2019) recently developed a vastly improved version of the 
Mitsunobu reaction which uses a phenol containing phosphine oxide in the +5 oxidation 
state that catalytically drives the reaction as a dual purpose oxidant and reductant, releasing 
only water as by product (Figure 27). Furthermore, they state that the number of substrates 
compatible with the reaction is increased compared to the “traditional” Mitsunobu. This 
both increases the reaction’s scope in future syntheses and removes several of the 

























Figure 27. Mechanism for catalytic Mitsunobu. Reprinted from “Redox-neutral 
organocatalytic Mitsunobu reactions.” By Beddoe, R. H., Andrews, K. G., Magné, V., 
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2) Ullmann Reaction: 
Our aim was to add a second solketal molecule at the 2-position to one of our compounds. 
We investigated a number of substitution reactions that may be used and found there are a 
few reactions that can be successful in this, such as Chan-Lam coupling (aryl NH2/OH as 
substrate, substituted boronic acid as reactant with Cu (II) as catalyst) (Munir et al., 2019). 
 
Figure 28. Chan-Lam Coupling. 
Or the Ullmann-type reaction (aryl bromide/iodide as substrate, substituted nucleophile as 
reagent with Cu (I) as catalyst) (Sambiagio, Marsden, Blacker, & McGowan, 2014). 
 
 
Figure 29. Ullman-Type Reaction. 
Ultimately, we selected the Ullmann reaction as preparation of the aryl bromide reaction 
substrate through the reaction of N-bromosuccinimide with 3-cyanophenol by electrophilic 
aromatic substitution was far easier than preparation of the required substituted boronic 
acid for Chan-Lam coupling. The Ullmann reaction we used is not a “true” Ullman coupling, 
as the classic reaction is generally used to prepare biaryl systems. We used a variation of 
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this which is essentially a copper-catalysed nucleophilic aromatic substitution of an aryl 
bromide with solketal as the nucleophile. 
Initially, we attempted this coupling with conditions as stated by Ma & Cai, (2003) (CuI, 
Cs2CO3, N,N-dimethylglycine, 1,4-dioxane). However, this resulted in no notable product 
formation. The reaction was re-attempted using conditions from Altman, Shafir, Choi, 
Lichtor, & Buchwald, (2008) (CuI, Cs2CO3, 3,4,7,8-tetramethyl-1,10-phenanthroline, 
toluene), which yielded complete conversion of starting material to product. This second 
procedure utilises commercially available 3,4,7,8-tetramethyl-1,10-phenanthroline as a 
ligand, which improves copper catalysed coupling reactions of aryl halides with a range of 
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Figure 30. Mechanism for the Ullmann reaction. Reprinted from “Ullmann Reaction” by 
Organic Chemistry Portal, n.d, Retrieved from https://www.organic-
chemistry.org/namedreactions/ullmann-reaction.shtm 
 
3) Nucleophilic Substitution: 
In searching for a good replacement for the Mitsunobu reaction to synthesise substituted 
benzonitriles, we considered the use of nucleophilic substitution. Investigation of literature 
gave several worthwhile methods, and we selected a reaction described in a patent by 
Smithkline Beecham (World Patent No. WO 2008/157273 A1, 2008), which involved 
nucleophilic substitution of a chlorine on 3,5-dichlorobenzonitrile with solketal sodium salt 
to give the substituted product. This was then able to be taken, deprotected and sulfated to 
give our final glycomimetic. 
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Figure 31. 1H NMR,13C NMR and structure of 3-chloro-5-([2,2-dimethyl-1,3-dioxolan-4-
yl]methoxy)benzonitrile. 
This reaction was extremely effective and gave product in high purity with good yield, as 
shown by the spectra in Figure 31 signified by only small peaks not corresponding to 
product. These spectra are quite similar to those in Figure 26 for compound 3, as they differ 
only in the position of the halogen and its substitution. Presence of product was confirmed 
through identification of the peaks which correspond to the solketal sidechain. The 
presence of aromatic protons was confirmed by the peaks shown at 7.1 – 7.4 ppm, 
integrating to 1 : 1 : 1 for a total of 3, as expected for a trisubstituted product. Peaks 
assigned to the solketal sidechain are as follows: 
1H NMR - 4.53 – 4.45 ppm (m, 1H), 4.19 ppm (dd, 1H), 4.09 – 3.97 ppm (m, 2H), 3.90 ppm 
(dd, 1H), 1.47 ppm (s, 3H) and 1.42 ppm (s, 3H). 
13C NMR - 110.00, 73.80, 69.41, 66.43, 26.80 and 25.22 ppm. 
Given the success of the initial substitution, we attempted to devise a procedure for a one-
pot synthesis of the 3,5-disubstituted species. Unfortunately, attempts at substituting 
positions 3 and 5 both together, and sequentially, gave only the 3-substituted product. This 
is likely due to changes in ring electronics, as loss of one chlorine electron withdrawing 
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group would deactivate the aromatic ring somewhat. Additionally, the substituted group is  
electron donating, further contributing to deactivating the ring, giving a deactivated species 
resistant to further nucleophilic attack.  
Furthermore, conditions for this reaction were somewhat tedious to maintain effectively, as 
the nucleophile is prepared in dry solvent with extremely water sensitive reagents (sodium 
hydride) and therefore must be done under completely dry conditions in order to get a good 
yield and success in the reaction. 
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2.4. Synthesis of final glycomimetics by sulfation/sulfonation: 
We aimed to prepare 3 categories of sulfates during these syntheses; Aryl sulfated and 
sulfonated glycomimetics, homochiral benzonitrile glycomimetics and racemic benzonitrile 
glycomimetics. Benzonitrile glycomimetics were selected for further investigation as, from 
our previous research (Bunte, 2017), have been shown to demonstrate good efficacy in 
inhibiting the HGF-Met pathway. 
Aryl glycomimetics were selected for investigation as there has been limited research into 
this class of molecules. We therefore synthesised a series of novel aryl sulfates and 
sulfonates, with an aim to effectively prevent cell mobility, and inhibit the HGF-Met 
pathway.  
Formation of the final compounds was achieved through sulfation of hydroxyl groups 
through 4 major routes, utilising SO3-amine complexes and chlorosulfonic acid as sources of 
sulfate. These routes and reagents were selected due to considerable research showing O-
sulfation under relatively mild conditions with generally high yields (Gill et al., 2019). Basic 
sulfations generally only required mild conditions, but reactions where sulfonation and aryl 
O-sulfation were required used harsher conditions with higher temperatures and more 
aggressive reagents. An exception to this is formation of phloroglucinol trisulfate, which 
required a different set of conditions to prevent formation of the sulfonate.  
Purification of the final compounds were carried out in a number of ways:  
1) Silica gel column chromatography utilising a highly polar solvent system (methanol or 2:1 
methanol : dichloromethane) due to the high polarity of the sulfated compounds. This had 
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its limitations and on occasion, the compound would elute containing a portion of the 
sulfate-amine salt due to lack of exchange of the amine with H+ on the silica gel. 
2) Preparation of the sulfate-potassium salt through the workup. This was generally the 
easiest to achieve, as purification, product isolation and formation of the alkali metal salt 
was easily completed in one workup step, then lyophilised to give the final dried product. 
3) Ion exchange with a sodium ion containing resin. If it was not possible to prepare the 
alkali metal salt in the workup, ion exchange was chosen for purification. Amberlite IR120 
Na was selected for use, and the compound passed though the resin in water, giving the 
pure sulfate sodium salt as product, which was then lyophilised to give the final dried 
sulfate. 
4) Isolation of the sulfate-tributylamine salt through aqueous workup, followed by reaction 
of the amine salt with sodium 2-ethylhexanoate to form the sulfate-sodium salt as final 
product, which was then lyophilised to give the final dried sulfate. 
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Initially, SO3-trimethylamine complex was used as the primary route for sulfation of alkyl 
hydroxyl groups and while effective, produced some considerable drawbacks. These consist 
of: 
1) using a high-boiling solvent which decomposes when heated aggressively, creating 
difficulties in evaporation.  
2) Extreme solubility of product in water, removing possibilities for aqueous workup, 
resulting in difficulties in purification.  
3) Formation of product-trimethylammonium salts which must be thoroughly removed 
through either ion exchange or column chromatography prior to cell testing due to the 
amine’s biological effect, which would affect test results. 
This sulfation was carried out according to Raiber et al., (2007) and utilised 2-3 equivalents 
of SO3-trimethylamine per OH group in N,N-dimethylformamide at 40 °C for 12 hours to 
fully sulfate the desired molecule. 
Furthermore, sulfation using sulfur trioxide trimethylamine complex is fast, easy and 
effective but generates a considerable quantity of impurities, which can be visualised in 
Figure 34 by the many small peaks distributed throughout the spectrum. While it is possible 
to identify the product from these spectra, it shows the necessity of thorough purification.  
Identification was achieved through assignment of the peaks to the propoxy sidechain, in 
addition to the upfield shift induced by the addition of several -OSO3 groups. Peaks assigned 
to the propoxy chain are as follows: 
1H NMR - 2.86 – 2.74 ppm (m, 2H), 2.69 – 2.56 ppm (m, 2H) and 2.56– 2.41 ppm (m, 1H). 
13C NMR - 71.55, 69.35 and 63.90 ppm 
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Further confirmation of reaction success was demonstrated by the aromatic protons 
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Figure 34. 1H NMR, 13C NMR and structure of 2-bromo-5-(2,3-
bis(sulfooxy)propoxy)benzonitrile. 
 
Synthesis of compound 24 by synthetic pathway C: 
 
Figure 35. Synthesis of potassium-4-methoxyphenyl sulfate using synthetic pathway C. 
Another route was used to prepare the aryl sulfates and sulfonates and was carried out 
according to the procedure by Burkhardt and Lapworth, with minor modifications, as 
suggested by Denehy, White, & Williams, (2006). This procedure required 1 equivalent of 
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This procedure utilised much harsher conditions than previous routes, due to the relatively 
high temperature and long reaction times. This procedure also resulted in some drawbacks, 
namely the length of workup that was required to give a relatively pure product free from 
pyridine, it was however free from all the major drawbacks outlined from Route: 1, as 
workups for this procedure addressed the problems of solubility, amine salts and solvent 
removal due to conversion to the potassium salt being achieved in the workup. This was 
done through basification of the compound with dilute KOH, washing with ethyl acetate at 
each step to exclude any pyridine or other impurities, followed by lyophilisation of the 
aqueous layer to yield the dried product. Yields of these aryl sulfates were generally 
moderate and preparation of the compounds was achieved quickly and easily. 
 
Figure 36. Synthesis of phloroglucinol trisulfate using synthetic pathway C. 
It was necessary to use a slightly different method, as suggested by Karimi-Jaberi, Pooladian, 
Moradi, & Ghasemi, (2012) in Route: 3 when preparing the phloroglucinol trisulfate, as using 
the harsher set of conditions outlined in the previous route gave 1,3,5-trihydroxy-2,4,6-
benzenetrisulfonic acid potassium salt as product. 
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Figure 37. Synthesis of 1,3,5-trihydroxy-2,4,6-benzenetrisulfonic acid potassium salt using 
synthetic pathway C. 
Therefore, another sulfation procedure was devised, using 1 equivalent of chlorosulfonic 
acid per OH group in dichloromethane at room temperature for a total of 4 hours to give 
phloroglucinol trisulfate as the final product. This route led to merely minor drawbacks, as 
no usage of SO3-amine complexes was necessary in addition to an easy workup being 
available. These were likely side reactions due to the high reactivity of chlorosulfonic acid, 
resulting in a lowered yield of 66%. 
This product was confirmed by investigation of the NMR spectra. Lack of peaks belonging to 
product in the 1H spectrum indicates the product having no C-H bonding, as expected for 
this product. The peak at 1.8 ppm is assigned to sodium acetate contamination, produced 
during the workup. The peak at 4.7 ppm is assigned to water contamination in D2O. 
The single peak at 181.50 ppm in the 13C spectrum indicates the 6 aromatic carbons present 
in this compound, allowing us to confirm product presence. The peak at 24 ppm is assigned 
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Figure 38. 1H NMR and 13C NMR of 1,3,5-trihydroxy-2,4,6-benzenetrisulfonic acid 
potassium salt. 
 
Figure 39. Synthesis of (S)-3-(2,3-bis(sulfooxy)propoxy)benzonitrile using sub-route A - 3. 
Upon further investigation of literature regarding O-sulfation of hydroxyl containing alkyl 
chains, a procedure which negated all major drawbacks was discovered by Gill, Male, & 
Jones (2019), who devised a synthesis of a novel SO3-amine complex which, with some 
preparation allows molecules to be sulfated in a similar way as outlined in Sub-route A-1. 
This procedure addresses the major issues of product isolation, purification and sulfate-
amine salt contamination by facilitating an aqueous workup to be undertaken, followed by 
preparation of its sodium salt through ion exchange. This gave us the ability to easily isolate 
our product, while simultaneously removing most of the major impurities in one step, as the 
tributylamine complex allowed the product to be soluble in organic solvents, and therefore 
easily extracted. Previously, this had not been possible as the sulfated compounds were 
highly soluble in water, leading to loss of product in the aqueous layer, which in turn, forced 
us to utilise much more labour-intensive purification techniques. Our synthesis using this 
procedure is outlined in Figure 39, and as mentioned, proceeds directly to the sodium salt 
without any labour-intensive purifications. 
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Unfortunately, this sulfating agent is not commercially available as yet and must be 
prepared though a relatively involved and time-consuming synthesis. This adds time and 
steps to an otherwise one-step reaction, however the benefits obtained from using this 
reagent far outweigh any negatives that may arise from the preparation of the reagent. 
 
 
Figure 40. Synthesis of sulfur trioxide tributylamine complex. 
The SO3-tributylamine reagent was prepared though the reaction of tributylamine with 
chlorosulfonic acid at -40 °C in dichloromethane, followed by pH adjustment with gaseous 
ammonia, isolation and lyophilisation to give the desired sulfating agent which was used 
directly in future sulfations to great success. The NMR of which can be seen in Figure 41, 
and corresponds directly to the NMR spectrum referenced in literature, allowing 
confirmation of product synthesis. 
Following sulfation of the target molecule, the sulfate-tributylammonium salt was subjected 
to ion exchange using sodium-2-ethylhexanoate in order to prepare the sulfate sodium salt, 
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Figure 41. 1H NMR of SO3 tributylamine complex. 
In general, sulfation of these compounds is relatively facile and discovery of improved 
reagents and methods have all but negated the drawbacks from earlier methods used in 
terms of product isolation, handling and purification, allowing us to not only make the 
preparation easier, but also much faster, increasing the throughput of sulfates. 
Purity is seen to be much higher as a result of this sulfation – ion exchange method as there 
is much less impurity present in the final product, shown in the spectra in Figure 42, when 
compared to Figure 34. which utilised the basic sulfation method using SO3 trimethylamine 
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2.5. Synthesis of substituted diarylmethanes by ortho lithiation: 
Ortho lithiation was selected for use in preparing more complex, substituted diarylmethane 
glycomimetic compounds, although this was found to be somewhat limited in scope, due to 
several difficulties faced in preparing the aryllithium species. 
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Figure 43. Overall reaction pathway for ortho lithiation. 
Firstly, we selected a simple substrate for determination of optimal conditions required for 
successful lithiation, compound 33. Synthesis of this was not, however, without difficulty. 
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Figure 44. Failed synthesis of 2,2-dimethyl-4-(phenoxy)methyl-1,3-dioxolane via 
asymmetric dihydroxylation using synthetic pathway D. 
Initially, we attempted asymmetric dihydroxylation of allyl phenyl ether to form compound 
32, then protection of the 2,3-diol by reaction with acetone catalysed by Amberlyst 15 H+ 
resin to give the acetonide. This reaction was unsuccessful as can be seen in Figure 45 at 
1.45 ppm, as the two methyl singlets for the acetonide dimethyl are very small and only 
integrate to around 0.6. This is further confirmed by the small aromatic peaks at 7.05 – 7.4 
ppm integrating to 0.1 which suggests that only 10% of compound 32 was converted to 
product, and therefore this reaction was deemed inviable.  
This is likely due to the fact that acetonide groups can both be formed (Yadav et al., 2014) 
and cleaved (Jumina et al., 2018) under acidic conditions, leading to an equilibrium which 
only allows a small of acetonide protected product to exist, resulting in very low product 
yield and therefore, reaction failure.  
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Figure 46. Synthesis of 2,2-dimethyl-4-(phenoxy)methyl-1,3-dioxolane through 2,2-
dimethyl-4-(tosyloxy)methyl-1,3-dioxolane using synthetic pathway D. 
Therefore, this synthesis was approached another way. Successful synthesis of a non-
enantiomeric version, compound 37 was attained through use of a tosylate intermediate 
(compound 35), prepared through the reaction of p-toluenesulfonyl chloride (p-TsCl) with 
solketal as shown in Figure 46, followed by coupling with phenol to give our desired 
product. Upon 1H NMR analysis, a portion of the acetonide had shown to have deprotected. 
This was due to the usage of impure p-TsCl containing an amount of p-toluenesulfonic acid 
in the preparation of the tosylate causing catalytic removal of the acetonide during 
coupling. This was remedied through purification of the p-TsCl through Soxhlet extraction in 
petroleum ether followed by reattempt at coupling with phenol. 
This gave the product in good purity and high yield, as shown in Figure 47. The 2 methyl 
singlets at 1.4 ppm which integrate to 3 : 3 for a total of 6 indicated the presence of the 
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acetonide dimethyl. The group of peaks at 3.75 – 4.55 ppm which integrate to a total of 5 
are assigned to the propoxy sidechain. Aromatic protons at 6.9 - 7.4 ppm which integrate to 
5 show monosubstitution on the aromatic ring. Together, these demonstrate successful 
synthesis of compound 37. Spectral data corresponded to that reported by Sugata, Tsubogo, 
Kino, & Uchiro, (2017)  
Data Obtained: 1H NMR (400 MHz, CDCl3) δ = 7.31 (2H, dd, J = 9.0, 7.2 Hz), 7.00 (1H, t, J = 7.2 
Hz), 6.94 (2H, d, J = 9.0 Hz), 4.51 (1H, m), 4.19 (1H, dd, J = 8.4, 6.6 Hz), 4.08 (1H, dd, J = 9.6, 
5.4 Hz), 3.96 (1H, dd, J = 9.6, 6.0 Hz), 3.93 (1H, dd, J = 8.4, 6.0 Hz), 1.50 (3H, s), 1.44 (3H, s)  
Data in Literature: 1H NMR (600 MHz, CDCl3) δ = 7.28 (2H, dd, J = 9.0, 7.2 Hz), 6.96 (1H, t, J = 
7.2 Hz), 6.91 (2H, d, J = 9.0 Hz), 4.48 (1H, m), 4.17 (1H, dd, J = 8.4, 6.6 Hz), 4.07 (1H, dd, J = 9.6, 
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Figure 47. 1H NMR of 2,2-dimethyl-4-(phenoxy)methyl-1,3-dioxolane. 
Conditions for lithiation at the ortho position were determined through several small-scale 
reactions using 2,2-dimethyl-4-(phenoxy)methyl-1,3-dioxolane. In determining these 
conditions, we trialled different reaction times, temperatures, solvents, additives and 
concentrations with various effects on yield and side-reactions.  
It was found that a relatively large excess of n-butyllithium (2.2 - 4 equivalents), TMEDA 
(equal quantity to n-BuLi), a relatively long reaction time (>3 h) and a comparatively high 
reaction temperature (0 °C) was required to efficiently form the aryllithium, evidence of 
which was determined by quenching all reactions with D2O, exchanging lithium with 
deuterium and indicating how much product had been formed, shown quantitively in the 1H 
NMR spectrum by removal of one proton from the ortho hydrogen peak at 7.27 ppm. The 




68 | P a g e  
Alexander Bunte 
 
Table 3. Reaction conditions against deuteration percentage. 
Reaction 
Number 







1 THF 0°C – 2 hours 1.1 9% 
2 THF 0°C – 2 hours 2.2 12% 
3 THF 0°C – 2 hours 2.2 + TMEDA 34% 
4 Ether 0°C – 2 hours 2.2 29% 
5 Ether 0°C – 4 hours 2.2 21% 
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Figure 48. 1H NMR of 2,2-dimethyl-4-(2-deuterophenoxy)methyl-1,3-dioxolane. 
Despite investigation of optimal reaction conditions, these trial reactions suffered from 
occasional failures. This may have been due to a number of factors, such as: insufficient 
reaction time, reaction temperature too low, old n-BuLi, incompatible reactant and 
substrate, inclusion of air and water, poor isolation of product on workup and choice of a 
too unreactive lithiating agent. In future, it may be worth testing other lithiating agents such 
as sec or tert-butyllithium as a more aggressive way to form the aryllithium species, in 
addition to longer reaction times and higher temperatures.  
Additionally, the substrate we used in these trials may not be comparable to that used in 
the synthesis of the diarylmethane. This could potentially affect how the reaction behaves 
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when introduced to a lithiating agent, therefore the conditions used in these trials are not 
representative of the reaction used to synthesise the diarylmethane. Future trial reactions 
utilising a substrate with a likeness closer to that of the reaction should be investigated, 
therefore giving us a better insight into how the reaction may proceed. 
 
Figure 49. Synthesis of 3-(2,3-dimethoxyphenylmethyl)benzonitrile using synthetic 
pathway F. 
Preparation of 3-(2,3-dimethoxyphenylmethyl)benzonitrile 40 was carried out according to 
methodology by Werle, Fey, Neudörfl, & Schmalz (2007). This reaction used 1.2 equivalents 
of n-butyllithium and 1.4 equivalents of TMEDA. Temperature was varied from 5 °C upon 
addition of n-butyllithium and increased to room temperature for 3.5 hours. Temperature 
was then decreased to -78 °C upon addition of the electrophile and slowly raised to 0 °C, 
then room temperature and allowed to stir overnight. This yielded the desired 
diarylmethane in moderate yield (63%). 
Synthesis of compound 40 was confirmed through interpretation of NMR spectra. Presence 
of the nitrile-substituted ring was indicated by peaks in the 1H NMR spectrum at 7.51 – 7.45 
ppm (m, 1H), 7.43 – 7.38 ppm (m, 1H) and 7.36 – 7.33 ppm (m, 2H) ppm for a total of 4 
protons, indicating a disubstituted ring. The second aromatic ring’s presence was confirmed 
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by peaks at 7.11 ppm (dd, 1H), 6.92 – 6.89 ppm (m, 1H) and 6.85 ppm (dd, 1H), integrating 
to a total of 3 protons, indicating a trisubstituted ring. 
The peak at 3.87 ppm (s, 2H) is assigned to the 2 protons linking both arenes together. The 
two peaks at 3.854 ppm (s, 3H) and 3.85 ppm (s, 3H) show the 2 methoxy groups integrating 
to a total of 6 protons.  
This is further reinforced by the 13C spectrum indicating 12 aromatic carbons at 153.99, 
148.90, 146.55, 141.96, 133.04, 131.99, 130.13, 129.38, 125.06, 124.80, 111.70 and 111.42 
ppm. The peak at 120.93 ppm is assigned to the nitrile and the two peaks at 60.56 and 55.83 
ppm correspond to the two methoxy groups. The final peak at 36.77 ppm is the carbon 
linking the two arenes together. 
This allows us to confirm the synthesis of compound 40. A moderate amount of impurities 
are present, signified by the large number of small peaks across the spectrum. To rectify 








Figure 50. 1H NMR and 13C NMR of 3-(2,3-dimethoxyphenylmethyl)benzonitrile. 
Unfortunately, due to time constraints, we were unable to finish this synthetic route. 
However, given more time, a series of substituted diarylmethane glycomimetic compounds 
may be synthesised, and tested for efficacy against the HGF-Met pathway. 
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2.6. Testing of synthesised compounds in cell viability and wound 
healing assays: 
Testing on DAOY cells was performed by Sonia Morlando at the University of Salford.  
1) Scratch wound healing assay: 
The Scratch assay was performed by seeding cells at density of 8000 cell/s per well in a 96 
well plate. After 24 h, RPMI 10% FBS media was replaced by RPMI 0% FBS and cells were 
under starvation for a day. Then, cells were pre-treated for 2 h with different concentrations 
of drug (specifically 1 mM-10 mM-100 mM) in triplicates and a scratch introduced in the 
well. Following MET activation with HGF 10 ng/ml, cells were incubated for 21 h in the 
BioTek Cytation 3 and pictures were taken every 30 minutes to evaluate wound closure. 
Conditions that the cells were monitored under are as follows: 

















Figure 51. Structure of (R)-3-(2,3-bis(sulfooxy)propoxy)benzonitrile sodium salt. 
 
Figure 52. Graph showing the effects of HGF, crizotinib and (R)-3-(2,3-
bis(sulfooxy)propoxy)benzonitrile sodium salt against wound size percent at 6- and 
12-hour intervals. 
At the both 6- and 12-hour marks, the HGF stimulated cells are showing rapid closure of the 
wound, as expected. Crizotinib is used as a benchmark, as it is an effective and proven 
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The drug shows relatively good activity at 1 µM concentration, improving slightly at 10 µM 
and falling slightly at the highest concentration of 100 µM. By the 12-hour mark, both HGF 
stimulated and unstimulated have closed the wound considerably, whereas drug treated 
cells are all showing the wound being mostly open. This suggests that this drug may have 







Figure 53. Structure of (S)-3-(2,3-bis(sulfooxy)propoxy)benzonitrile sodium salt. 
Figure 54. Graph showing the effects of HGF, crizotinib and (S)-3-(2,3-
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In the (S)-enantiomer, HGF stimulated, unstimulated and crizotinib treated cells have near 
identical results to the (R)-enantiomer, as expected. However, the (S)-enantiomer, has a 
much lesser effect at 1 and 10 µM concentrations, with a much higher effect at 100 µM 
keeping the wound near fully open, improving on that of crizotinib. This compound shows 
very good activity at high concentration, and with optimisation could potentially be 


































Scratch Assay after 24 hours: DAOY Compound 8  
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Figure 56. Graph showing the effects of HGF, crizotinib and 2,5-bis-(2,3-
bis(sulfooxy)propoxy)benzonitrile against wound size percent after 24 hours. 
Following a 24-hour period, HGF stimulated cells have closed the wound 98% of the way. 
Cells treated with 2,5-bis-(2,3-bis(sulfooxy)propoxy)benzonitrile 8 show slightly accelerated 
wound closure at 1 µM, increasing at both 10 and 100 µM, signified by faster wound closure 
than the untreated cells. It is however, decelerated compared to the HGF stimulated cells. 
Stimulation of cell motility is sometimes seen in these compounds, which may allow them to 
be used as a “dual purpose” drug, with some compounds showing inhibition of motility and 
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Figure 58. Graph showing the effects of HGF, crizotinib and 1,3,5-trihydroxy-2,4,6-
benzenetrisulfonic acid potassium salt against wound size percent after 24 hours. 
1,3,5-Trihydroxy-2,4,6-benzenetrisulfonic acid potassium salt 26, however showed 
extremely strong activity at only 1 µM, slightly improving at 10 µM, with the efficacy falling 
to that of Crizotinib at 100 µM. Efficacy at 1 and 10 µM is around twice that of crizotinib. 
This compound has shown the best inhibition of cell motility tested so far and should be 
thoroughly investigated as a potential lead. 
Testing on DAOY cells was performed by Sonia Morlando at the University of Salford.  
2) MTT Cell Viability Assay: 
In this assay, the toxicity of the drug against the cells is investigated in order to determine 
whether the drug is cytotoxic, which in our case would be undesirable, as these compounds 
are designed to have no cytotoxic activity. 
For the short-term proliferation assay, cells were seeded in a 96 well plate at density of 
2000 cells/well for DAOY, ONS76 and MB03. After 24 h of incubation at 37° with 5% CO2 




























Scratch Assay after 24 hours: DAOY Compound 26
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(GAGs mimics) and 10 mM (Tivantinib). MTT assay was performed after 72 h of treatment 
adding 50 mL of thiazolyl blue tetrazolium bromide 3 mg/ml (Alfa Aesar) in each well. 
Following 3 h of incubation, MTT solution was dissolved in DMSO and the optical density 
was measured at 540 nM by using a microplate reader (FLUOstar Omega). All the results 
were normalized to controls and analysed using GraphPad Prism 5 software. In order to 
evaluate how DAOY and MB03 cells respond to tivantinib long treatment (9 days) we seeded 
cells at density of 200 per well in a 96 well plate. After 24 h of incubation, we treated cells 
three times within intervals of three days. Tivantinib treatment was performed in 
quadruplicates with drug at eight different concentration with dilution 1:10 starting at 10 
μM. After 9 days, cells were stained with 0.5% Crystal Violet to assess cell viability. Plate was 
washed with normal water and stain was dissolved by adding 100 μL of methanol. 
Absorbance was measured at 540 nM and analysis was performed with GraphPad Prism 5 
software. 
 
Cell viability stayed at its highest level until 
reaching a concentration of 10-2  µM, 
suggesting that this compound is not 
extremely cytotoxic, as it only starts to have 
effects on cells at high concentration of 
drug. 
 
Figure 59. Graph showing the effect of (R)-3-(2,3-bis(sulfooxy)propoxy)benzonitrile 
sodium salt on DAOY cell viability at varying concentrations. 
 
 




Here, cell viability decreased at only a 
concentration of 10-6 µM, therefore this 
compound is more cytotoxic than its 
enantiomer, possibly due to impurities 
having a cytotoxic effect, as its similar 
structure should not cause such a large 
discrepancy in cell toxicity. 
 
Figure 60. Graph showing the effect of (S)-3-(2,3-bis(sulfooxy)propoxy)benzonitrile 































Figure 61. Graphs showing the structures and effects of compounds 6, 8, 17, 24 25, 26 
and 27 on DAOY cell viability at varying concentrations. 
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As shown in the group of graphs in Figure 61, as compounds 6, 8, 17, 24, 25, 26 and 27  all 
have a negligible effect on cell viability at all concentrations, as expected due to the 
compounds synthesised having little to no cytotoxic activity. 
 
3. Experimental: 
3.1. General Experimental: 
Unless otherwise stated, all materials were obtained from Sigma Aldrich, Fluorochem, Alfa 
Aesar or Fischer Scientific and used as-is without further purification. 
Analytical TLC was performed using Fischer Scientific aluminium backed silica gel 60 Å F254 
sheets (0.25 mm thickness) and analysed using a 254 nm UV lamp. 
Purifications were carried out by Flash Column Chromatography using Fischer Scientific silica 
gel 60 Å (200-400 mesh) and commercial laboratory-grade solvents obtained from Fischer 
Scientific. 
All 1H and 13C NMR spectroscopy was performed by myself at Salford University on a Bruker 
Ultrashield 400 MHz spectrometer at ambient temperature and edited using Bruker Topspin 
software. 
Testing of compounds on cells was performed by Sonia Morlando at Salford University on 
DAOY cell lines. 
Mass Spectrometry was performed by Lee Harman at Manchester Metropolitan University 
on an Agilent 6540 LC-Q-ToF spectrometer at ambient temperature. 
All NMR solvents were purchased from Cambridge Isotope Laboratories and used as-is. 
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FTIR spectra were recorded at Salford University by myself as a thin film using a Varian FTIR 
spectrometer at ambient temperature and edited using Thermo Fisher OMNIC software. 
Anhydrous solvents were obtained from Sigma Aldrich in individual 100 mL SureSeal TM 
bottles and backfilled with argon following each use. Dry reaction conditions were achieved 
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3.2. Materials and Methods: 
3.2.1. Synthesis of 2-bromo-5-hydroxybenzonitrile: 
 
3-Cyanophenol (1.5 g, 12.6 mmol) was dissolved in acetonitrile (15 mL). Boron trifluoride 
diethyl etherate (1.55 mL, 12.6 mmol) was added dropwise, followed by n-
bromosuccinimide (2.24 g, 12.6 mmol) and allowed to stir for 12 h at room temperature. 
The reaction was then quenched through the addition of saturated aqueous ammonium 
chloride (5 mL) and the mixture extracted with ethyl acetate (2 x 25 mL). The combined 
organic extracts were washed with water (2 x 25 mL), brine (15 mL), dried over magnesium 
sulfate and concentrated in vacuo to afford an off-white powder which was subjected to 
column chromatography (3 : 1 ethyl acetate : hexanes) to give 2-bromo-5-
hydroxybenzonitrile as a white powder (2.3 g, 91.8%).  
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3.2.2. Synthesis of 2-bromo-5-allyloxybenzonitrile: 
 
2-Bromo-5-hydroxybenzonitrile (0.5 g, 2.52 mmol) was dissolved in anhydrous acetone (20 
mL) and added to a flask containing potassium carbonate (700 mg, 5 mmol) in anhydrous 
acetone (2 mL) at 0°C. Following 1 h stirring at 0°C, allyl bromide (0.3 mL, 3.7 mmol) and 
tetrabutylammonium iodide (185 mg, 0.5 mmol) were added and the reaction allowed to 
stir for 16 h at room temperature. Acetone was then evaporated in vacuo and the mixture 
diluted with ethyl acetate (20 mL), the organics washed with water (3 x 20 mL), brine (20 
mL), dried over magnesium sulfate and concentrated in vacuo to afford 2-bromo-5-
allyloxybenzonitrile as a yellow oil (0.498 g, 83%).  
1H NMR (CDCl3, 400 MHz): δ 7.54 (d, J = 8.96 Hz, 1H), 7.16 (d, J = 3.00 Hz, 1H), 7.03 (dd, J = 
8.96, 3.00 Hz, 1H), 6.02 (m, 1H), 5.42, (dd, J = 17.27, 1.37 Hz, 1H) 5.34, (dd, J = 10.53, 1.37 
Hz, 1H) 4.55 (dt, 5.24, 1.43 Hz, 2H). 
13C NMR (CDCl3, 400 MHz): δ 157.63, 134.00, 131.84, 121.52, 119.78, 118.69, 118.46, 
117.28, 116.18, 69.41.  
High-resolution mass spectroscopy (ESI+): (M+H)+: calculated for C10H8BrNO, 237.9868; 
found 237.9862.  
IR: 2233, 1672, 1240, 582, cm-1. 
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3.2.3. Synthesis of 2-bromo-5-[(2,2-dimethyl-1,3-dioxolan-4-
yl)methoxy]benzonitrile: 
 
Under argon at 0°C, diisopropyl azodicarboxylate (0.63 mL, 3.24 mmol) was added dropwise 
to a solution 2-bromo-5-hydroxybenzonitrile (367.3 mg, 1.845 mmol), solketal (0.405 mL, 
2.24 mmol) and triphenylphosphine (849 mg, 3.24 mmol) in dry tetrahydrofuran (3.5 mL), 
and the reaction allowed to stir for 16 h at room temperature. Solvents were then removed 
in vacuo to give a dark yellow oil that was subjected to column chromatography (3 : 1 
petroleum ether 40-60 : ethyl acetate) to give 2-bromo-5-[(2,2-dimethyl-1,3-dioxolan-4-
yl)methoxy]benzonitrile as a yellow oil (250 mg, 43.5%). 
1H NMR (CDCl3, 400 MHz): δ 7.48 (d, J = 8.96 Hz, 1H), 7.11 (d, J = 3.01 Hz, 1H), 6.97 (dd, J = 
8.96, 3.01 Hz, 1H), 4.36 - 4.40 (m, 1H), 4.10, (dd, J = 8.57, 6.50 Hz, 1H) 3.86 – 4.00, (m, 2H) 
3.81 (dd, 8.57, 5.73 Hz, 1H), 1.38 (s, 3H), 1.33 (s, 3H). 
13C NMR (CDCl3, 400 MHz): δ 157.68, 134.05, 121.31, 119.60, 116.96, 116.25, 116.15, 
110.10, 73.66, 69.42, 66.41, 26.75, 25.26. 
High-resolution mass spectroscopy (ESI+): (M+H)+: calculated for C13H14BrNO3, 312.0235; 
found 312.0233.  
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3.2.4. Synthesis of 2-bromo-5-(2,3-dihydroxypropoxy)benzonitrile: 
 
p-Toluenesulfonic acid (4 mg, 0.02 mmol) was added to a solution of 2-bromo-5-[(2,2-
dimethyl-1,3-dioxolan-4-yl)methoxy]benzonitrile (60 mg, 0.2 mmol) in methanol (1 mL) and 
allowed to stir for 16 h. The solution was then diluted with dichloromethane (20 mL), 
washed with saturated aqueous sodium bicarbonate solution (15 mL), water (3 x 10 mL), 
brine (10 mL), dried over magnesium sulfate and concentrated in vacuo to afford 2-bromo-
5-(2,3-dihydroxypropoxy)benzonitrile as a thick yellow oil (27 mg, 49.6%). 
1H NMR (CDCl3, 400 MHz): δ 7.58 (d, J = 8.96 Hz, 1H), 7.21 (d, J = 3.00 Hz, 1H), 7.05 (dd, J = , 
8.96, 3.00 Hz, 1H),  4.12 – 4.2 (m, 1H), 4.08 (d, J = 0.83 Hz, 1H), 3.73 – 3.93 (m, 2H), 2.54 (d, J 
= 4.64 Hz, 1H). 
13C NMR (CDCl3, 400 MHz): δ 157.56, 134.21, 121.16, 119.79, 116.97, 116.34, 116.03, 70.06, 
69.85, 63.45. 
High-resolution mass spectroscopy (ESI+): (M+H)+: calculated for C10H10BrNO3, 271.9922; 
found 271.9919.  
IR: 3419, 2932, 2234, 1242, 586  cm-1. 
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3.2.5. Synthesis of 2,5-bis-[(2,2-dimethyl-1,3-dioxolan-4-
yl)methoxy]benzonitrile: 
 
To an oven-dried screw cap vial was added copper (I) iodide (3.05 mg, 0.016 mmol), 3,4,7,8-
tetramethyl-1,10-phenanthroline (7.56 mg, 0.032 mmol), caesium carbonate (208.5 mg, 
0.04 mmol) and solketal (79 µL, 0.064 mmol) under argon atmosphere. 2-bromo-5-[(2,2-
dimethyl-1,3-dioxolan-4-yl)methoxy]benzonitrile (100 mg, 0.32 mmol) in dry toluene (0.5 
mL) was added to the vial by syringe. The reaction was then capped, heated to 80°C in an oil 
bath and stirred vigorously for 16 h. The mixture was then cooled to room temperature, 
diluted with ethyl acetate (20 mL) and washed with water (3 x 15 mL), brine (15 mL), dried 
over magnesium sulfate and concentrated in vacuo to give 2,5-bis-[(2,2-dimethyl-1,3-
dioxolan-4-yl)methoxy]benzonitrile as a dark brown oil (58 mg, 95%). 
1H NMR (CDCl3, 400 MHz): δ 7.55 (d, J = 8.95 Hz, 1H), 7.19 (d, J = 3.00 Hz, 1H), 7.04 (dd, J = , 
8.95, 3.00 Hz, 1H), 4.51 – 4.44 (m, 1H), 4.28 – 4.21 (m, 1H), 4.17 (dd, J = 8.28, 1.74 Hz, 1H), 
4.14 – 4.09 (m, 1H), 4.07 – 3.94 (m, 2H), 3.89 (dd, J = 8.57, 5.76 Hz, 1H), 3.80 (dd, J = 8.21, 
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6.52 Hz, 1H), 3.73 (d, J = 3.73 Hz, 1H), 3.62 (d, J = 5.10 Hz, 1H), 1.46 (s, 3H), 1.45 (s, 3H), 1,40 
(s, 3H), 1.38 (s, 3H). 
13C NMR (CDCl3, 400 MHz): δ 157.67, 134.06, 121.29, 119.58, 116.95, 116.29, 116.17, 
110.09, 109.41, 73.65, 69.41, 66.42, 65.66, 62.99, 26.71, 25.26. 
High-resolution mass spectroscopy (ESI+): (M+H)+: calculated for C19H25NO6, 364.1760; 
found 364.1758.  
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3.2.6. Synthesis of 2,5-bis-(2,3-dihydroxypropoxy)benzonitrile: 
 
Amberlyst 15 H+ (60mg) was added to a solution of bis-2,5-[(2,2-dimethyl-1,3-dioxolan-4-
yl)methoxy]benzonitrile (54 mg, 0.148 mmol) in methanol (3 mL) and allowed to stir for 16 
h. The resulting solution was decanted off, and the resin washed with methanol (3 x 10 mL). 
The combined organics were evaporated in vacuo to afford 2,5-bis-(2,3-
dihydroxypropoxy)benzonitrile as a brown oil (24 mg, 50%). 
1H NMR (CDCl3, 400 MHz): δ 7.46 (d, J = 8.96 Hz, 1H), 7.09 (d, J = 3.00 Hz, 1H), 6.94 (dd, J = 
8.96, 3.00 Hz, 1H), 4.07 – 4.01 (m, 1H), 3.98 – 3.91  (m, 4H), 3.79 – 3.62 (m, 4H), 3.61 – 3.54 
(m, 1H). 
13C NMR (CDCl3, 400 MHz): δ 157.72, 134.09, 121.28, 119.77, 116.98, 116.18, 116.14, 70.17, 
69.78, 64.03, 63.38. 
High-resolution mass spectroscopy (ESI+): (M+H)+: calculated for C13H17NO6, 284.1134; 
found 284.1130.  
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3.2.7. Synthesis of 2-bromo-5-(2,3-bis(sulfooxy)propoxy)benzonitrile: 
 
To a solution of 2-bromo-5-(2,3-dihydroxypropoxy)benzonitrile (27 mg, 0.1 mmol) in dry 
N,N-dimethylformamide (1 mL) was added sulfur trioxide trimethylamine complex (55.6 mg, 
0.4 mmol) and the reaction heated to 40°C and allowed to stir for 16 h. Solvents were then 
removed in vacuo by azeotropic distillation using toluene/xylenes. Any remaining solvent 
residue was removed under high-vacuum to give a thick, dark yellow oil which was 
subjected to column chromatography (4 : 1 methanol : dichloromethane) to give 2-bromo-5-
(2,3-bis(sulfooxy)propoxy)benzonitrile as a thick yellow oil (36 mg, 90.6%). 
1H NMR (MeOD, 400 MHz): δ 6.21 (dd, J = 8.90, 1.09 Hz, 1H), 5.90 (dd, J = 13.31, 3.02 Hz, 
1H), 5.74 – 5.67 (m, 1H), 2.86 – 2.74 (m, 2H), 2.69 – 2.56  (m, 2H), 2.56– 2.41 (m, 1H). 
13C NMR (MeOD, 400 MHz): δ 159.95, 135.33, 122.93, 121.21, 117.99, 117.03, 116.21, 
71.55, 69.35, 63.90. 
High-resolution mass spectroscopy (ESI+): (M+H)+: calculated for C10H8BrNO9S2, 429.8902; 
found 429.8897.  
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3.2.8. Synthesis of 2,5-bis-(2,3-bis(sulfooxy)propoxy)benzonitrile: 
 
To a solution of 2,5-bis-(2,3-dihydroxypropoxy)benzonitrile (25 mg, 0.088 mmol) in dry N,N-
dimethylformamide (1 mL) was added sulfur trioxide trimethylamine complex (53 mg, 0.38 
mmol) and the reaction heated to 40°C and allowed to stir for 16 h. Solvents were then 
removed in vacuo by azeotropic distillation using toluene/xylenes. Any remaining solvent 
residue was removed under high-vacuum to give a thick, dark yellow oil which was 
subjected to column chromatography (methanol) to give 2,5-bis-(2,3-
bis(sulfooxy)propoxy)benzonitrile as a thick yellow oil (30 mg, 83.3%). 
1H NMR (MeOD, 400 MHz): δ 7.69 (d, J = 8.99 Hz, 1H), 7.44 (dd, J = 8.62, 3.00 Hz, 1H), 7.28  – 
7.22 (m, 1H), 4.30 (dd, J = 15.56, 4.99 Hz, 1H), 4.19 (dd, J = 10.00, 3.05 Hz, 1H), 4.12 – 4.06 
(m, 4H), 4.04 (d, J = 5.89 Hz, 1H), 3.71 – 3.66 (m, 1H), 3.64 (d, J = 5.00 Hz, 1H), 3.60 (d, J = 
5.80 Hz, 1H) 
13C NMR (D2O, 400 MHz): δ 155.23, 130.29, 120.18, 119.27, 114.32, 114.03, 113.98, 68.58, 
63.14, 62.27. 
High-resolution mass spectroscopy (ESI+): (M+H)+: calculated for C13H13NO18S4, 599.9094; 
found 599.9089.  
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3.2.9. Synthesis of 3-chloro-5-([2,2-dimethyl-1,3-dioxolan-4-
yl]methoxy)benzonitrile: 
 
Sodium hydride (60% dispersion in mineral oil) (75.9 mg, 2.26 mmol) was added to a pre-
dried round bottomed flask under argon atmosphere and washed with petroleum ether 40-
60°C to remove any trace mineral oils. To the flask was then added dry N,N-
dimethylformamide (3 mL) and cooled to 0°C. Solketal (0.27 mL, 1.914 mmol) was then 
added dropwise over 2 minutes, then allowed to stir at 0°C until any gas evolution ceased. 
3,5-dichlorobenzonitrile (0.3g, 1.74 mmol) in dry N,N-dimethylformamide (2 mL) was then 
added slowly over 2 minutes and the reaction allowed to warm to room temperature and 
stir for 16 h. Following this, the mixture was poured into ice-cold 10% v/v HCl solution, 
extracted with ethyl acetate (2 x 30 mL), washed with water (3 x 15 mL), brine (15 mL), dried 
over magnesium sulfate and concentrated in vacuo to afford 3-chloro-5-([2,2-dimethyl-4-
dioxolan-4-yl]methoxy)benzonitrile as a thick yellow oil (0.352 g, 75.6%). 
1H NMR (CDCl3, 400 MHz): δ 7.26 (t, J = 1.53 Hz, 1H), 7.18 (t, J = 2.11 Hz, 1H), 7.11  – 7.09 (m, 
1H), 4.53 – 4.45 (m, 1H), 4.19 (dd, J = 8.58, 6.49, 1H), 4.09 – 3.97 (m, 2H), 3.90 (dd, J = 8.58, 
5.67 Hz, 1H), 1.47 (s, 3H), 1.42 (s, 3H). 
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13C NMR (CDCl3, 400 MHz): δ 159.32, 136.01, 124.52, 120.20, 117.40, 116.70, 114.20, 
110.00, 73.80, 69.41, 66.43, 26.80, 25.22. 
High-resolution mass spectroscopy (ESI+): (M+H)+: calculated for C13H14ClNO3, 268.0741; 
found 268.0736.  
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3.2.10. Synthesis of 3-chloro-5-(2,3-dihydroxypropoxy)benzonitrile: 
 
This synthesis was attempted using 2 different reactions. 
Reaction 1: 
To a stirred solution of 3-chloro-5-([2,2-dimethyl-4-dioxolan-4-yl]methoxy)benzonitrile (150 
mg, 0.56 mmol) in methanol (2.5 mL) was added para-toluenesulfonic acid (13 mg, 0.068 
mmol) in one portion and allowed to stir for 16 h at room temperature. Following this, the 
mixture was diluted with dichloromethane (40 mL), washed with saturated aqueous sodium 
bicarbonate solution (20 mL), water (2 x 20 mL), dried over magnesium sulfate and 
concentrated in vacuo to afford 3-chloro-5-(2,3-dihydroxypropoxy)benzonitrile as a thick 
dark yellow gel (50 mg, 39.6%). 
1H NMR (CDCl3, 400 MHz): δ 7.26 (t, J = 1.45 Hz, 1H), 7.18 (t, J = 2.08 Hz, 1H), 7.11  – 7.09 (m, 
1H), 4.18 – 4.10 (m, 1H), 4.10 – 4.02 (m, 2H), 3.87 – 3.71 (m, 2H). 
13C NMR (CDCl3, 400 MHz): δ 159.36, 136.04, 124.48, 120.17, 117.44, 116.55, 114.02, 70.18, 
69.73, 69.30. 
High-resolution mass spectroscopy (ESI+): (M+H)+: calculated for C10H10ClNO3, 228.0428; 
found 228.0422.  
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Amberlyst 15 H+ (200 mg) was added to a solution of 3-chloro-5-([2,2-dimethyl-4-dioxolan-
4-yl]methoxy)benzonitrile (54 mg, 0.148 mmol) in methanol (10 mL) and allowed to stir for 
16 h. The resulting solution was decanted off, and the resin washed with methanol (3 x 10 
mL). The combined organics were evaporated in vacuo to afford 3-chloro-5-(2,3-
dihydroxypropoxy)benzonitrile as a thick dark yellow oil (0.166 g, 93%). 
1H NMR (CDCl3, 400 MHz): δ 7.26 (t, J = 1.45 Hz, 1H), 7.18 (t, J = 2.08 Hz, 1H), 7.11  – 7.09 (m, 
1H), 4.18 – 4.10 (m, 1H), 4.10 – 4.02 (m, 2H), 3.87 – 3.71 (m, 2H), 
13C NMR (CDCl3, 400 MHz): δ 159.36, 136.04, 124.48, 120.17, 117.44, 116.55, 114.02, 70.18, 
69.73, 69.30 
High-resolution mass spectroscopy (ESI+): (M+H)+: calculated for C10H10ClNO3, 228.0428; 
found 228.0423.  
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3.2.11. Synthesis of (R)-3-(2,3-dihydroxypropoxy)benzene: 
 
AD-mix α (5.5 g) was added to a round bottomed flask and dissolved in equal volumes tert-
butanol and water totalling 60 mL and cooled to 0°C. Allyl phenyl ether (0.5 g, 3.726 mmol) 
and methanesulfonamide (0.372 g, 3.912 mmol) were added in one portion to the reaction 
and the reaction allowed to stir at 0°C for 16 h. The reaction was then quenched through 
the addition of sodium sulfite (3.25 g, 25.7 mmol). Solvents were removed in vacuo and 
methanol (40 mL) was added to the resulting salt and heated at reflux for 1 h. Concentration 
of the filtrate in vacuo afforded (R)-3-(2,3-dihydroxypropoxy)benzene as a thick yellow oil 
(0.547 g, 87.5%).  
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3.2.12. Synthesis of 3-chloro-5-(2,3-bis(sulfooxy)propoxy)benzonitrile: 
 
To a solution of 3-chloro-5-(2,3-dihydroxypropoxy)benzonitrile (158mg, 0.694 mmol) in 
anhydrous N,N-dimethylformamide (3.5 mL) was added sulfur trioxide trimethylamine 
complex (0.386 g, 2.77 mmol) and the reaction was allowed to stir at 40°C for 16 h. Solvent 
was removed in vacuo as an azeotrope with toluene. Any remaining solvents were removed 
under high vacuum. The crude product was dissolved in methanol and filtered through a 
cotton plug. Collection and concentration of the filtrate in vacuo gave 3-chloro-5-(2,3-
bis(sulfooxy)propoxy)benzonitrile as a dark yellow gel (221 mg, 82.6%). 
1H NMR (MeOD, 400 MHz): δ 7.26 (t, J = 1.47 Hz, 1H), 7.18 (t, J = 2.09 Hz, 1H), 7.11  – 7.09 
(m, 1H), 4.43 – 4.27 (m, 4H), 4.21 – 4.11 (m, 1H). 
13C NMR (MeOD, 400 MHz): δ 161.28, 137.17, 127.62, 125.46, 121.58, 118.08, 115.54, 
75.52, 68.65, 55.41. 
High-resolution mass spectroscopy (ESI+): (M+H)+: calculated for C10H8ClNO9S2, 385.9407; 
found 385.9402.  
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3.2.13. Synthesis of 2,2-dimethyl-4-(tosyloxy)methyl-1,3-dioxolane: 
 
Para-toluenesulfonyl chloride was placed in a Soxhlet thimble and placed into the extractor. 
The collecting flask was filled with petroleum ether 40-60°C, insulated and the extraction 
process started. The extractor was allowed to function for 3 h, after which it was allowed to 
cool. Purified para-toluenesulfonyl chloride slowly crystallised out of the petroleum ether 
and was vacuum filtered to obtain the pure product. Remaining solids in the extraction 
thimble were discarded. 
Freshly purified para-toluenesulfonyl chloride (4 g, 20.98 mmol) was added portionwise to a 
solution of solketal (2.5 g, 18.91 mmol) in pyridine (5 mL) at 0°C. The resulting mixture was 
slowly brought to room temperature and allowed to stir for 16 h. Pyridine is removed in 
vacuo and the residue diluted with ethyl acetate (25 mL), washed with cold 1M HCl solution 
(40 mL), saturated aqueous sodium bicarbonate solution (25 mL), brine (25 mL), dried over 
magnesium sulfate and concentrated in vacuo to afford 2,2-dimethyl-4-(tosyloxy)methyl-
1,3-dioxolane as white crystals (4.84 g, 89.46%). 
Spectral data corresponded to that found in literature (Krupa, Chodyński, Ostaszewska, 





104 | P a g e  
Alexander Bunte 
3.2.14. Synthesis of 2,2-dimethyl-4-(phenoxy)methyl-1,3-dioxolane: 
 
 
Sodium hydroxide (0.44 g, 11 mmol) was added portionwise to a stirred solution of phenol 
(1g, 11 mmol) in ethanol/water (3:1, 4 mL). Following stirring for 10 min, a solution of 2,2-
Dimethyl-1,3-dioxolane-4-methanol p-toluenesulfonate (2.1 g, 7.34 mmol) in ethanol (2.5 
mL) was added dropwise to the reaction over 1 minute. The reaction was then heated at 
reflux for 20 h. Following this, solvents were removed in vacuo, and the residue treated with 
10% w/v sodium hydroxide solution (5 mL). The treated residue was then extracted with 
dichloromethane (3 x 10 mL), the combined organics washed with water (3 x 10 mL), brine 
(10 mL), dried over magnesium sulfate and concentrated in vacuo to give 2,2-dimethyl-4-
(phenoxy)methyl-1,3-dioxolane as an off-white powder. (1.1 g, 48.08%).  
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3.2.15: Synthesis of 2,2-dimethyl-4-(2-deuterophenoxy)methyl-1,3-dioxolane: 
General procedure for preparation of 2,2-dimethyl-4-(2-deuterophenoxy)methyl-1,3-
dioxolane: 
 
2,2-Dimethyl-4-(phenoxy)methyl-1,3-dioxolane (50mg, 0.236 mmol) was added to a pre-
dried 2-necked round bottomed flask under argon atmosphere and dissolved in 
anhydrous solvent (5 mL). After cooling to 0°C, n-butyllithium 1.6M in hexanes (1.1 – 2.2 
equivalents) were added dropwise over 2 minutes. Following stirring at 0°C for 2 hours, 
the reaction was quenched through addition of D2O (0.5 mL). The mixture was then 
diluted with ether (20 mL), dried over magnesium sulfate, filtered and concentration of 
the filtrate in vacuo afforded the deuterated product.  
1H NMR (400 MHz, CDCl3) δ = 7.28 (dd, J = 9.0, 7.2 Hz, 2H), 6.91 (d, J = 9.0 Hz, 2H), 4.48 
(m, 1H), 4.17 (dd, J = 8.4, 6.6 Hz, 1H), 4.07 (dd, J = 9.6, 5.4 Hz, 1H), 3.94 (dd, J = 9.6, 6.0 
Hz, 1H), 3.91 (dd, J = 8.4, 6.0 Hz, 1H), 1.47 (s, 3H), 1.41 (s, 3H). 
13C NMR (400 MHz, CDCl3) δ = 157.35, 130.25, 121.11, 116.52, 108.95, 74.63, 68.92, 
67.32, 27.25, 25.04. 
High-resolution mass spectroscopy (ESI+): (M+H)+: calculated for C10H15DO3, 210.1241; 
found 210.1235.  
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Solvent Reaction Time and 
temperature 
Equivalents of n-
butyllithium and additives 
1 THF 0°C – 2 hours 1.1 
2 THF 0°C – 2 hours 2.2 
3 THF 0°C – 2 hours 2.2 + TMEDA 
4 Ether 0°C – 2 hours 2.2 
5 Ether 0°C – 4 hours 2.2 
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3.2.16. General procedure for aryl sulfate preparation: 
Sulfur trioxide pyridine complex (1 equivalent per OH group) was added to a stirred solution 
of substituted phenol (8.4 mmol) in toluene (15 mL) and allowed to stir at reflux for 16 h. 
Following this the toluene was decanted off and the residue dissolved in distilled water (5 
mL). 0.2M KOH solution was added to the crude mixture until it indicated basic on pH paper, 
followed by washing with ethyl acetate (3 x 20 mL). The basic solution was then acidified 
through addition of glacial acetic acid, washed with ethyl acetate (3 x 20 mL) and re-basified 
through addition of 0.2M KOH. The remaining solvent was removed in vacuo to give the 
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Synthesis of potassium 4-methoxyphenyl sulfate: 
 
 
The reaction yielded potassium 4-methoxyphenyl sulfate as a white powder (1.4 g, 76.43%) 
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Synthesis of potassium 3-cyanophenyl sulfate: 
 
The reaction yielded potassium 3-cyanophenyl sulfate as an off-white powder (1.31 g, 
73.03%) 
Spectral data corresponded to that found in literature (Montero Bastidas, Oleskey, Miller, 
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Synthesis of 1,3,5-trihydroxy-2,4,6-benzenetrisulfonic acid potassium salt: 
 
The reaction yielded 1,3,5-trihydroxy-2,4,6-benzenetrisulfonic acid potassium salt as a 
brown solid (2.2 g, 60.56%)  
1H NMR (400 MHz, D2O) - No shifts observed. 
13C NMR (400 MHz, D2O) δ = 181.50 
High-resolution mass spectroscopy (ESI+): (M+3K)3+: calculated for C6H3K3O12S3, 479.7698; 
found 479.7692.  
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Synthesis of 3,5-bis(sulfooxy)benzoate potassium salt: 
 
The reaction yielded methyl 3,5-bis(sulfooxy)benzoate potassium salt as a light brown solid 
(2.11 g, 69.01%) 
1H NMR (400 MHz, D2O) δ = 7.56 (d, J = 2.26 Hz, 1H), 7.31 (t, J = 2.24 Hz, 1H), 6.66 (t, J = 
2.30, 1H), 1.82 (3H, s). 
13C NMR (400 MHz, D2O) δ = 151.36, 139.31, 119.56, 117.69, 110.20, 107.46, 58.63. 
High-resolution mass spectroscopy (ESI+): (M+2K)2+: calculated for C8H6K2O10S2, 403.8677; 
found 403.8672.  
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Synthesis of methyl-3,5-bis(sulfooxy)benzene potassium salt: 
 
The reaction yielded methyl-3,5-bis(sulfooxy)benzene potassium salt as a light brown solid 
(2.01 g, 73.76%) 
1H NMR (400 MHz, D2O) δ = 6.32 (d, J = 6.97 Hz, 2H), 6.25 (t, J = 2.11 Hz, 1H), 1.82 (s, 3H). 
13C NMR (400 MHz, D2O) δ = 155.02, 153.33, 115.40, 113.18, 21.53. 
High-resolution mass spectroscopy (ESI+): (M+2K)2+: calculated for C7H6K2O8S2, 359.8778; 
found 359.8773.  
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Synthesis of 2,5-bis(sulfooxy)benzoic acid: 
 
The reaction yielded 2,5-bis(sulfooxy)benzoic acid potassium salt as a light brown solid (1.9 
g, 64.37%) 
1H NMR (400 MHz, D2O) δ = 7.77 (d, J = 3.05 Hz, 1H), 7.68 (d, J = 3.02 Hz, 1H), 7.58 (d, J = 
2.99 Hz, 1H) 
13C NMR (400 MHz, D2O) δ = 174.52, 157.81, 143.17, 127.32, 125.53, 123.15, 117.20. 
High-resolution mass spectroscopy (ESI+): (M+2K)2+: calculated for C7H4K2O10S2, 389.8520; 
found 389.8517.  
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3.8.17. Synthesis of phloroglucinol trisulfate: 
 
To a flask containing phloroglucinol (0.525 g, 4.16 mmol) was added a solution of 
chlorosulfonic acid (1.46 g, 12.5 mmol) in DCM (5 mL) over a period of 1 h at room 
temperature. Following addition of the acid solution, the mixture was stirred for 3 h at room 
temperature, followed by removal of the solvent in vacuo. The resulting solid was washed 
with n-hexanes (5 mL), filtered and dried to give phloroglucinol trisulfate as a light brown 
solid. (1.33 g, 66.27%) 
1H NMR (400 MHz, D2O) δ = 5.92 (s, 1H), 5.86 (s, 1H), 5.83 (s, 1H). 
13C NMR (400 MHz, D2O) δ = 155.81, 106.05. 
High-resolution mass spectroscopy (ESI+): (M+H)+: calculated for C6H6O12S3, 366.9100; 
found 366.9093 
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3.2.18. Synthesis of 3-allyloxybenzonitrile: 
 
3-cyanophenol (2 g, 23.2 mmol) was dissolved in anhydrous acetone (50 mL) and added to a 
flask containing potassium carbonate (4.64 g, 33.6 mmol) in anhydrous acetone (5 mL) at 
0°C. Following 1 h stirring at 0°C, allyl bromide (1.7 mL, 23.2 mmol) and 
tetrabutylammonium iodide (1.22 g, 3.3 mmol) were added and the reaction allowed to stir 
for 16 h at room temperature. Acetone was then evaporated in vacuo and the mixture 
diluted with ethyl acetate (60 mL), the organics washed with water (3 x 40 mL), brine (40 
mL), dried over magnesium sulfate and concentrated in vacuo to afford 3-
allyloxybenzonitrile as a yellow oil (2.54 g, 94.46%) 
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3.2.19. Synthesis of (R)-3-(2,3-dihydroxypropoxy)benzonitrile: 
 
AD-mix α (5 g) was added to a round bottomed flask and dissolved in equal volumes tert-
butanol and water totalling 40 mL and cooled to 0°C. 3-allyloxy benzonitrile (0.3 g, 1.886 
mmol) and methanesulfonamide (0.224 g, 2.338 mmol) were added in one portion to the 
reaction and the reaction allowed to stir at 0°C for 16 h. The reaction was then quenched 
through the addition of sodium sulfite (3 g, 23.8 mmol). Solvents were removed in vacuo 
and methanol (30 mL) was added to the resulting salt and heated at reflux for 1 h. 
Concentration of the filtrate in vacuo afforded (R)-3-(2,3-dihydroxypropoxy)benzonitrile as a 
thick yellow oil (0.364 g, 81.87%) 
Spectral data corresponded to that found in literature (Bredikhin, Bredikhina, Akhatova, 








117 | P a g e  
Alexander Bunte 
3.2.20. Synthesis of (S)-3-(2,3-dihydroxypropoxy)benzonitrile: 
 
 
AD-mix ß (5 g) was added to a round bottomed flask and dissolved in equal volumes tert-
butanol and water totalling 40 mL and cooled to 0°C. 3-allyloxy benzonitrile (0.3 g, 1.886 
mmol) and methanesulfonamide (0.224 g, 2.338 mmol) were added in one portion to the 
reaction and the reaction allowed to stir at 0°C for 16 h. The reaction was then quenched 
through the addition of sodium sulfite (3 g, 23.8 mmol). Solvents were removed in vacuo 
and methanol (30 mL) was added to the resulting salt and heated at reflux for 1 h. 
Concentration of the filtrate in vacuo afforded (S)-3-(2,3-dihydroxypropoxy)benzonitrile as a 
thick yellow oil (0.317 g, 87.09%) 
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3.2.21. Synthesis of sulfur trioxide tributylamine complex: 
 
To a pre-dried 3-necked round-bottomed flask under argon atmosphere was added 
anhydrous dichloromethane (200 mL) and tributylamine (59.4 mL, 0.25 mol) under vigorous 
stirring and cooling to -40°C (MeCN / CO2). To a pressure-equalising dropping funnel was 
then added a solution of chlorosulfonic acid (16.75 mL, 0.253 mol) in anhydrous 
dichloromethane (200 mL) and allowed to add slowly over 2 h ensuring the internal 
temperature did not exceed -30°C. Following addition of the acid solution, the reaction was 
allowed to stir for another 1 h at -40°C after which, gaseous ammonia was bubbled through 
the reaction mixture until pH 7 was achieved. The white solid was removed through vacuum 
filtration, washed with dichloromethane (100 mL) and the filtrate collected. Solvents were 
then removed in vacuo and the remaining crude product was treated with cold water (500 
mL). The resulting precipitate was collected, washed with water (5 x 100 mL) and lyophilised 
to give sulfur trioxide tributylamine complex as a fine white powder. (57.4 g, 86.65%) 
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3.2.22. Synthesis of (S)-3-(2,3-bis(sulfooxy)propoxy)benzonitrile sodium salt: 
 
(S)-3-(2,3-dihydroxypropoxy)benzonitrile (0.3 g, 1.55 mmol) and sulfur trioxide tributylamine 
complex (1.24 g, 6.2 mmol) were added to a pre-dried round-bottomed flask under argon 
atmosphere and dissolved in anhydrous acetonitrile (8 mL), heated to 40°C and allowed to 
stir for 16 h. Following this, the reaction was cooled to room temperature, and solvents 
removed in vacuo. Water (30 mL) was added to the flask and the aqueous mixture was 
extracted with ethyl acetate (4 x 40 mL). Organic extracts were combined, dried over 
magnesium sulfate and filtered. The filtrate solvent was removed in vacuo to give the crude 
sulfate tributylammonium salt.  
The tributylammonium salt was then dissolved in ethanol (50 mL) and to the solution was 
added sodium-2-ethylhexanoate (2.58 g, 15.5 mmol) and the mixture stirred vigorously for 1 
h at room temperature. Solids were removed by filtration, collected and washed with 
ethanol (3 x 30 mL) and dried to give (S)-3-(2,3-bis(sulfooxy)propoxy)benzonitrile sodium 
salt as a white powder. (0.485g, 78.73%) 
1H NMR (400 MHz, D2O) δ = 7.40 (t, J = 8.06 Hz, 1H), 7.36 – 7.30 (m, 2H), 7.29 – 7.24 (m, 1H), 
4.85 – 4.74 (m, 1H),  4.39 - 4.20 (m, 4H). 
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13C NMR (400 MHz, D2O) δ = 157.88, 130.81, 125.70, 120.67, 119.46, 118.12, 111.85, 75.1, 
66.6, 40.5. 
High-resolution mass spectroscopy (ESI+): (M+2Na)2+: calculated for C10H9NNa2O9S2, 
396.9514; found 396.9510.  
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3.2.23. Synthesis of (R)-3-(2,3-bis(sulfooxy)propoxy)benzonitrile sodium salt: 
 
(S)-3-(2,3-dihydroxypropoxy)benzonitrile (0.225 g, 1.16 mmol) and sulfur trioxide 
tributylamine complex (1.24 g, 4.66 mmol) were added to a pre-dried round-bottomed flask 
under argon atmosphere and dissolved in anhydrous acetonitrile (6 mL), heated to 40°C and 
allowed to stir for 16 h. Following this, the reaction was cooled to room temperature, and 
solvents removed in vacuo. Water (30 mL) was added to the flask and the aqueous mixture 
was extracted with ethyl acetate (4 x 40 mL). Organic extracts were combined, dried over 
magnesium sulfate and filtered. The filtrate solvent was removed in vacuo to give the crude 
sulfate tributylammonium salt.  
The tributylammonium salt was then dissolved in ethanol (50 mL) and to the solution was 
added sodium-2-ethylhexanoate (1.94 g, 11.7 mmol) and the mixture stirred vigorously for 1 
h at room temperature. Solids were removed by filtration, collected and washed with 
ethanol (3 x 30 mL) and dried to give (R)-3-(2,3-bis(sulfooxy)propoxy)benzonitrile sodium 
salt as a white powder. (0.352 g, 76.32%)  
1H NMR (400 MHz, D2O) δ = 7.40 (t, J = 8.07 Hz, 1H), 7.36 – 7.30 (m, 2H), 7.29 – 7.24 (m, 1H), 
4.86 - 4.77 (m, 1H),  4.41 - 4.19 (m, 4H). 
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13C NMR (400 MHz, D2O) δ = 157.88, 130.81, 125.70, 120.67, 119.46, 118.12, 111.85, 75.1, 
66.6, 40.5. 
High-resolution mass spectroscopy (ESI+): (M+2Na)2+: calculated for C10H9NNa2O9S2, 
396.9514; found 396.9510. 
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3.2.24. General procedure for ortho lithiation: 
 
A solution of 2,2-dimethyl-4-(phenoxy)methyl-1,3-dioxolane (50 mg, 0.26 mmol) and a 
chosen quantity of freshly distilled anhydrous TMEDA in anhydrous solvent (5 mL) was 
added to a pre-dried round-bottomed flask under argon atmosphere and allowed to cool to 
0°C. A chosen quantity of n-butyllithium 1.6M in hexanes was added dropwise over 5 
minutes, then allowed to stir at 0°C for 3.5 h. Following this, the electrophile was added, 
and the reaction allowed to warm to room temperature and stir for 16 h. The reaction is 
then diluted through the addition of solvent (20 mL) and washed with water (3 x 15 mL), 
brine (15 mL), dried over magnesium sulfate, filtered, and the filtrate concentrated in vacuo 













Table 6. Reactants and reaction conditions for syntheses MR18 - 25. 
Compound Electrophile Equivalents of n-
butyllithium and 
additives 
Reaction time + 
Temperature 
Yield 
MR18 MeI 2.2 + TMEDA 3.5 h - 0°C 15% 
MR19 Allyl bromide 2.2 + TMEDA 3 h - 0°C 30% 
MR20 Allyl bromide 4 + TMEDA - TBME 2 h - 0°C 5% 
MR21 Allyl bromide 7 + TMEDA 2 h - 0°C 40% 
MR22 Benzyl 
bromide 
2.2 + TMEDA 2 h - 0 °C 24% 
MR23 TMS-Cl 2.2 + TMEDA 2 h - 0°C Complex 
Mixture 
MR24 TMS-Cl 7 + TMEDA 2 h - 0°C Complex 
Mixture 
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3.2.25. Synthesis of 3-(2,3-dimethoxyphenylmethyl)benzonitrile: 
 
A solution of 1,2-dimethoxy benzene (1.1 mL, 8.63 mmol) and freshly distilled anhydrous 
TMEDA (1.82 mL, 12.1 mmol) in anhydrous THF (25 mL) was added to a pre-dried round-
bottomed flask under argon atmosphere and allowed to cool to 5°C. n-Butyllithium 1.6M in 
hexanes (6.47 mL, 10.4 mmol) was added dropwise over 5 minutes, then allowed to stir at 
room temperature for 3.5 h. Following this, the reaction was cooled to -78°C (CO2 / acetone) 
and a solution of 3-(bromomethyl) benzonitrile (2 g, 10.4 mmol) in anhydrous THF (5 mL) 
was added over 1 minute, the reaction allowed to warm to 0°C and stir for 1 h, followed by 
room temperature for 16 h. The suspension was then cooled to 10°C, quenched through 
addition of saturated NH4Cl solution (25 mL). The aqueous phase was separated, extracted 
with THF (3 x 40 mL), the organics combined, dried over magnesium sulfate, filtered, and 
the filtrate concentrated in vacuo to give 3-(2,3-dimethoxyphenylmethyl)benzonitrile as an 
off-white solid (1.37 g, 62.84%) 
1H NMR (400 MHz, CDCl3) δ = 7.51 – 7.45 (m, 1H), 7.43 – 7.38 (m, 1H), 7.36 – 7.33 (m, 2H), 
7.11 (dd, J = 8.00, 1.45 Hz, 1H), 6.92 – 6.89 (m, 1H), 6.85 (dd, J = 8.28, 1.47 Hz, 1H), 3.87 (s, 
2H), 3.854 (s, 3H), 3.85 (s, 3H). 
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13C NMR (400 MHz, CDCl3) δ = 153.99, 148.90, 146.55, 141.96, 133.04, 131.99, 130.13, 
129.38, 125.06, 124.80, 120.93, 111.70, 111.42, 60.56, 55.83, 36.77. 
High-resolution mass spectroscopy (ESI+): (M+H)+: calculated for 254.1181; found 254.1175.  
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Conclusion: 
Throughout this project, several improvements in order to streamline the synthesis of these 
inhibitors have been made. Firstly, the development of a one-pot procedure to synthesise 
both aryl sulfates and sulfonates allows us to quickly and effectively convert both 
commercially available substituted phenols and more complex, lab-synthesised phenols into 
potential HGF-Met inhibitors, which are then able to be tested for efficacy in inhibiting cell 
mobility. Unfortunately, the synthesis of these compounds generally results in moderate 
yields. Development of a better synthetic route which increases both yield and purity would 
be advantageous and should be considered in future research. 
Secondly, major improvements in the synthesis of these glycomimetic compounds have 
been recently developed which have allowed us to easily synthesise, then purify target 
compounds in a small amount of time and steps through the use of novel reagents and 
techniques. Usage of SO3 tributylamine complex has allowed us to exchange the use of 
complex, highly polar and difficult separations by column chromatography with common 
solvent-based workups followed by facile ion exchange procedures, not previously available 
in the synthesis and purification of these glycomimetics. 
Testing of our compounds showed some positive results in terms of inhibiting cell motility in 
wound healing assays at moderate to low molar concentrations. With improvements to the 
SAR of these compounds, it may be possible to make these inhibitors more effective at 
lower concentrations through implementation of different, more effective sidechains or 
substitution of different aryl-bonded groups with a higher efficacy. 
Unfortunately, due to time limitations, it was not possible to synthesise a diarylmethane 
derived series of compounds, however given further time and resources it would be 
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possible to produce a number of various substituted diarylmethanes and investigate their 
activities against cell motility.  
Additionally, further investigation into different sulfation types such as N-sulfation have not 
been trialled in the production and testing of HGF-Met inhibitors as of yet and warrants 
investigation. Synthesis of more aryl sulfate and sulfonate compounds is also necessary as 
there is little data on their effectiveness as HGF-Met inhibitors and testing a wider range of 
compounds would allow us to create a set of data on the efficacy of these compounds. 
Overall, we have demonstrated that synthesis of several small molecule HGF-Met inhibitors 
can be achieved at high yield through a relatively short and effective synthesis, with some 
compounds showing good activity against cell motility at relatively low molar 
concentrations, with little effects on cell viability. Further research into development of 
these compounds should be considered as a better SAR may be derived and used to further 
improve these HGF-Met inhibitors allowing higher efficacy at lower molar concentrations.  
 
Future Work: 
The research presented in this thesis begins to address the use of polysulfated 
glycosaminoglycans as HGF-Met inhibitors as a way to reduce metastasis through reducing 
cell motility. While some success in preventing cell motility was achieved with the structures 
depicted in section 2.6, there are many more structures to be investigated which may 
potentially have higher efficacy than the ones synthesised during this research project. 
Firstly, it is not completely certain yet what exactly drives the SAR of these molecules. 
Further work would involve modifying structures with known efficacy and determining 
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which moieties are responsible for increasing efficacy and specificity, while lowering 
cytotoxicity. Research should also be conducted into whether enantiomers do in fact play a 
critical part in providing any higher or lower activity of the synthesised compound. 
As discussed in the conclusion, N-Sulfation is one direction that has not been investigated 
yet in the synthesis and testing of HGF-Met inhibitors and could potentially hold some 
valuable results as to date, our research has only focused on O- sulfation. Therefore, 
investigation of this class of molecule is well worth the time, as it is possible that N- sulfated 
compounds have a much better efficacy when compared to O- sulfated compounds. 
Another area that should be investigated is further methods which may allow us to 
streamline our syntheses. At present our current syntheses are relatively short and easy to 
obtain the final compound in few steps, with facile solvent-based workups. This however 
generally results in moderate yields. Investigation into development of a synthetic 
pathway/workup which does not result in a large loss of yield would be advantageous and 
should be considered in future to allow simpler purifications and larger amounts of material, 
which in turn will make potential longer syntheses much more attainable. 
Further research should also be considered into larger molecules, such as the 
diarylmethane-based compounds which we did not have sufficient time to look into, as 
discussed above, could have the potential to have a very good SAR and be better candidates 
for inhibition when compared to the current compounds we have investigated. 
Addressing these future areas could allow us to improve the SAR of our compounds, and 
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